Background: Acquired von Willebrand syndrome (AvWS) represents an acquired quantitative or qualitative defect in von Willebrand factor (vWF) that may result in clinical bleeding. AvWS is known to be associated with various disease states, including myeloproliferative disorders, paraproteinemias, solid tumors, autoimmune disorders, and hormonal alterations. Specifi cally, AvWS has been well-described in pediatric patients with Wilms tumor (WT). The incidence of this complication is high, with estimates of laboratory-confi rmed AvWS ranging from 8 to 30 percent. The pathogenesis underlying this association is unknown, although mechanisms involving secreted hyaluronic acid and/or sequestration of vWF by tumor cells have been proposed. We herein present (1) the largest immunohistochemical study to date of surface vWF labeling in WT and (2) to our knowledge, the fi rst study to explore a potential etiologic link between WT and AvWS-namely, the expression of glycoprotein 1b (GP1b), a component of the canonical vWF-binding GP1b-9-5 surface receptor complex, by WT cells. Design: We retrospectively collected 28 cases of WT and 26 control cases from the archived clinical specimens of the Department of Pathology at the University of California, San Francisco Medical Center. Control cases consisted of 16 clear cell renal cell carcinomas (RCCs), 5 papillary RCCs, 2 chromophobe RCCs, 2 clear cell papillary RCCs, and 1 rhabdoid tumor of kidney. AvWS-related clinical and laboratory data were obtained for all patients. Immunohistochemical (IHC) staining for both vWF and GP1b were performed on all cases at ARUP Laboratories (Salt Lake City, Utah). Results: 7 of 28 patients with WT (25%) experienced clinical bleeding episodes which were suspicious for a bleeding diathesis. AvWS laboratory parameters were available in only 1 WT patient with clinical bleeding but were not diagnostic for AvWS. Tumor cells from WT and control cases did not exhibit membranous staining with either vWF or GP1b. Patchy, nonspecifi c cytoplasmic staining for vWF was noted in a minority of cases, predominantly occurring in stromal cells.
HSCT patients with diarrea (n=50)
TMA
Conclusions:
We identifi ed histologic features of iTMA that are useful to delineate GI vascular injuries in post-HSCT patients. Recognition of these histological signs in patients with GI symptoms may guide early treatments for iTMA.
Pulmonary Pathology (including Mediastinal)

Idiopathic Tracheal Stenosis Emine Bozkurtlar, Hironori Uruga, Lida Hariri, Mari Mino-Kenudson, Eugene
Mark. Marmara University, Istanbul, Turkey; Toranomon Hospital, Tokyo, Japan; Massachusetts General Hospital, Boston, MA. Background: Tracheal stenosis causing respiratory difficulty that prompts surgical correction in adults commonly is due to prior intubation or trauma. A subset of patients with tracheal stenosis have no such underlying cause. The great majority of patients are female. Familial disease has been reported. Design: We previously reported on idiopathic tracheal stenosis not related to trauma in 63 cases. Here we report an additional one hundred and twenty-two cases with a clinical diagnosis of idiopathic tracheal stenosis seen over the last six years by the Thoracic Surgery Service at our hospital. We analyzed histopathology, principally with hematoxylin and eosin staining, stressing the location and character of the scarring. We excluded cases that might have been associated with Wegener's granulomatosis, relapsing ploychondritis, amyloid, or other. We principally studied whole cross sections of resected trachea. Because the disease is virtually limited to women, we studied estrogen and progesterone receptors. ANCA had been measured in some cases. Results: Our prior report emphasized the character of dense fibrosis and preserved inner perichondrium of tracheal cartilage. In this reprot we concentrate on dilatation of mucus glands and ducts, which were observed in 30% or more of cases. The dilatation ranged from two or more times normal diameter of the duct. The larger dilatation lesions were filled with mucus or proteinaceous material. Many smaller ducts which had dilatation lesions were surrounded by circumferential myxoid fibrosis. A lymphoplasmacytic infiltrate was observed in many cases. In our cohort seventy-two cases were evaluated for estrogen and progesterone receptors. 78% of cases were positive for estrogen receptor and 80% for progesterone receptor. We established three grades for lymphoplasmacytic infiltrate, with the infiltrate from none to marked. Only one patient had even borderline elevation of ANCA. All but four patients were females. Conclusions: Idiopathic tracheal stenosis, also termed idiopathic laryngotracheal stenosis, has distinctive pathology, both in terms of the character of the fibrosis and in terms of ductular dilatation and periductal fibrosis, which has some aspects are reminiscent of bronchiolitis as can be seen in collagen-vascular diseases.
SOX-2 Expression and Its Prognostic Value in Stage II and III Lung Adenocarcinomas
Emine Bozkurtlar, Hironori Uruga, Tiffany Huynh, Michael Lanuti, Eugene Mark, Mari Mino-Kenudson. Massachusetts General Hospital, Boston, MA. Background: SOX-2 is a transcription factor that has been found overexpressed in some types of poorly differentiated carcinomas. It is associated with better prognosis in lung squamous cell carcinoma (SCC) but its expression and prognostic significance in lung adenocarcinoma (ADC) are controversial. In particular, little is known about the role of SOX-2 expression in predicting response to therapies. The aim of this study was to examine SOX-2 expression in advanced stage ADC and correlate it with clinicopathological parameters and patient outcomes with respect to adjuvant therapy status.
Design: Immunohistochemistry for SOX-2 was performed in 112 surgically resected stage II and III ADCs consisting of 61 and 51 cases with and without adjuvant therapies, respectively. Nuclear expression of SOX-2 was evaluated using H score (calculated based on the intensity of nuclear staining and the percentage of positive tumor cells: maximum 300). H score >10 was used as a cut-off for positive SOX-2 expression. SOX-2 expression was correlated with clinicopathological features and patient outcomes. Results: Positive SOX-2 expression was seen in 55% (62) of the entire cohort, 57.5% (35) of the adjuvant therapy group and 43.5% (27) of the non-adjuvant therapy group. There was a trend toward higher stage tumors exhibiting SOX-2 expression (p=0.08). Histologically, there was correlation between SOX-2 positivity and predominant micropapillary pattern (p=0.02). Whereas solid predominant pattern was not associated with SOX-2 positivity, SOX-2 was often expressed in regions with solid pattern in tumors with heterogeneous histology, and SOX-2 expression was associated with the presence of solid pattern in >10% of the tumor cells (p=0.03). No other clinicopathological features including smoking history were associated with SOX-2 expression in stage II and III ADCs. Among the patients who underwent adjuvant therapies, five-year recurrence free survival was 31.7% and 51.9% in the SOX-2 positive and negative groups, respectively. Conversely, there was no difference in survival between the 2 groups among those without adjuvant therapies. Conclusions: SOX-2 expression is associated with high-grade histologic patterns and likely dictates unfavorable outcomes after adjuvant therapy in advanced stage ADCs. The finding suggests the possibility of SOX-2 to be a marker for resistance to adjuvant therapy in ADC opposed to a lineage specific marker predicting favorable outcomes in SCC.
P40 and GATA-3 Are Useful To Distinguish Between Lung Squamous Cell Carcinoma and Triple Negative Breast Cancer
Elena Brachtel, Tiffany Huynh, Mari Mino-Kenudson. Massachusetts General Hospital, Boston, MA. Background: Patients with lung nodules or mediastinal lymphadenopathy often undergo fine needle aspiration biopsy to confirm malignancy and primary site. To distinguish between non-small cell lung cancer with squamous differentiation (LSCC) and triplenegative breast cancer (TNBC), a heterogenous subtype which also includes spindle cell carcinomas, is particularly difficult in small samples. This study evaluates commonly used immunohistochemical markers in diagnostically validated lung and breast cancers. Design: Diagnostically confirmed formalin-fixed paraffin-embedded tissue samples from 90 patients with LSCC, 67 TNBC of various morphologies and 45 estrogenreceptor positive (ER+) breast cancers were selected. Tissue microarrays were prepared and immunohistochemically stained by routine procedures with an automated stainer and reagents. Cytoplasmic staining for napsin A, GCDFP-15 and mammaglobin (MG), and nuclear staining for TTF-1, p40, and GATA-3 was assessed semiquantitatively. Stain intensity was scored as 0 (negative), 1 (faint) and 2 (strong), extent as 0 (negative), 1 (<10%), 2 (10-50%), and 3 (>50% positive).
Results:
As expected, all LSCC showed strong p40 expression, and were negative for napsin A and TTF-1; no significant staining was seen with mammary markers (GATA-3, GCDFP-15 and MG). Most TNBC showed GATA-3 expression (68%), with a few cases expressing p40 (5%) and several cases with faint TTF-1. All ER+ breast cancers expressed GATA-3 and no p40. Conclusions: This side-by-side comparison of several lung and breast diagnostic markers on diagnostically validated cases shows p40 and GATA-3 as the most useful immunomarkers to differentiate between TNBC and LSCC. LSCC consistently express p40 but none of the other lung and breast markers tested in this study. Most TNBC express GATA-3 with only few positive for p40. Small tissue samples obtained at lung and mediastinal biopsies determine treatment and effective diagnostic markers are of utmost importance.
anomalies resulting in protein loss have been reported in sporadic MM. We evaluated the usefulness of BAP1 expression in the differential diagnosis between MM and RMP in tissue and cytological samples. Design: Mouse monoclonal antibody anti-BAP1 (clone C-4) was applied on biopsies from MM (208 cases), benign mesothelial tumors (BMT)(12) and RMP (39, 12 with atypical features [AMP] ); RMP included 29 pleural and 1 peritoneal samples obtained during evaluation of recurrent effusion and/or thoracoscopic anomalies; this group was followed clinically and/or radiologically for variable periods of time (up to 9 years). BAP1 stain was also performed in 63 cytological samples (40 MM, 23 RMP, including 6 AMP). BAP1 expression was evaluated in cell nuclei. Results: BAP1 was positive in all BMT; 137/208 MM were BAP1-, with higher frequency in epithelioid/biphasic subtype (135/195, 69.2%) . BAP1 loss was easily recognizable since all tumor cells lacked protein expression; in BAP1-MM superficial mesothelium was also negative, independently from the degree of atypia. Thirty-six RMP (11 AMP) were BAP1+; 3 of them (2 AMP) developed BAP1+ MM. BAP1 loss was found in 3 patients with RMP (1 AMP), 2 developed BAP1-MM within two years, one (AMP) died of intra-abdominal metastasis after 4 years. BAP1 reactivity on cytological samples was also easily assessed; tumor cells in 25/40 (62.5%) MM were BAP1-; 4/23 RMP were BAP1-, all were AMP and later diagnosed as BAP1-MM. Conclusions: BAP1 loss is frequently found in epithelioid/biphasic MM; it has an absolute specificity (100%) in the differential with RMP both in tissue and cytological samples and, in contrast to other markers, its evaluation is straightforward (present/ absent). RPM cases with BAP1 loss should be carefully re-evaluated, likely representing non invasive MM. BAP1 stain might also be useful in the study of tumor extent in resectable BAP1-MM.
Histological Difference Between Idiopathic Interstitial Pneumonias and Connective Tissue Disease-Associated Interstitial Pneumonias
Mutsumi Dairiki, Hiromi Ichikawa, Tomonori Tanaka, Hiroyuki Taniguchi, Takeshi Johkoh, Kensuke Kataoka, Yasuhiro Kondoh, Junya Fukuoka . Nagasaki University School of Medicine, Nagasaki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Nagasaki University Hospital, Nagasaki, Japan; Tosei General Hospital, Seto, Aichi, Japan; Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan. Background: Idiopathic interstitial pneumonias (IIPs) and connective tissue disease (CTD)-associated interstitial pneumonias (IPs) are the two most common types of IPs. CTD-IPs and IIPs share common histological features, yet the clinical managements are different. Separation of the two conditions solely by histology is challenging, and there are no established criteria. Design: We selected consecutive 106 IIPs (80 IPF-UIP and 26 idiopathic NSIP) and 56 cases of CTD-IPs (21 RA, 12 SSc, 13 PM/DM, 7 SjS, and 3 MCTD). Whole slide images of all specimens in 200x magnification were prepared. Eighteen histological factors were evaluated by 2 observers independently and graded semi-quantitatively into score of 0 to 3. The consensus scores were obtained afterwards by the discussion which also includes another pulmonary pathologist. Association between the score of each markers and diagnosis of CTD was investigated using qui square and Fisher's exact test.
Results: Histological markers positively suggestive for IIPs were dense fibrosis (p<0.01), microscopic honeycomb (p<0.01), fibroblastic focus (p<0.01), smooth muscle hyperplasia (p<0.01), and interstitial giant cells (p=0.02). Markers positively suggestive for CTD-IPs were extensive pleuritis (p<0.01), lymphoid aggregates with germinal center (p<0.01), prominent plasmacytic infiltration (p<0.01), and airspace fibrin (p=0.02). When histological pattern was limited to UIP, histological markers suggestive for IPF-UIP were fibroblastic focus (p=0.02) and smooth muscle hyperplasia (p=0.04).
On the other hand, markers suggestive for CTD-UIP were extensive pleuritis (p=0.04), lymphoid aggregates with germinal center (p<0.01), prominent plasmacytic infiltration (p<0.01), and fat metaplasia (p=0.04). When NSIP was considered, dense fibrosis (p=0.04), smooth muscle hyperplasia (p<0.01), and dense perivascular collagen (p=0.04) associated with idiopathic-NSIP, however, none associated positively with CTD-NSIP.
Conclusions:
We identified the histological markers distinguishing CTD-IPs from IIPs: extensive pleuritis, lymphoid aggregates with germinal center, prominent plasmacytic infiltration. The value of these histological markers as diagnostic criteria for CTD-IPs should be further confirmed.
Comprehensive Genomic Profiling (CGP) of 44 RET-Fused Lung Adenocarcinomas (LADCA) With Histologic and Clinical Correlates
Julia Elvin, Sanjay Mukhopadhyay, Siraj Ali, Kai Wang, Mark Bailey, Vamsidhar Velcheti, Yuan Li, Norma Palma, Rachel Erlich, Doron Lipson, Roman Yelensky, Juliann Chmielecki, Philip Stephens, Vincent Miller, Jeffrey Results: RET-fused LADCA patients were relatively young (48.8y) and more often women (27F, 17M). Advanced stage (85% III/IV, 16% < II/unk), lymphatic involvement (50% primary), pleural spread (23%), and symptomatic effusion (11.4%) were noted, despite small primary tumor size (reported in 10 cases; pT1a 80%; pT1b 20%). RET was most commonly fused to KIF5B (64%) and CCDC6 (18%), but one fusion to each of NCOA4, TRIM33, ZNF477P, ERCC1, HTR4, CLIP1, and 2 intragenic RET rearrangements was identified. The most common predominant histologic pattern was solid (55%), with cribriform (18%), micropapillary (14%) and papillary (7%) patterns accounting for the remainder. Histologic pattern did not correlate with fusion partner. At least a small micropapillary component was present in 47%. Co-occurring homozygous deletion of CDKN2A/B (p14/p16; 25%) was present almost exclusively in the cases lacking a micropapillary component. At least one additional GA occurred in 90% including p53, MDM2, SETD2, CTNNB1, MYC alterations. However, there were no cases with concurrent ALK or RAS alterations. Of note, the NCOA4-RET case was originally called negative by RET break-apart FISH assay and had no other co-occurring known driver mutations detected. Conclusions: RET-fused LADCA show a predilection for women and occur at a relatively young mean age. Most are solid-pattern predominant, but a micropapillary component is common. KIF5B and CCDC6 are the most common, but not the only, oncogenic fusion partners. Since there are no pathognomonic clinical or morphologic features, CGP is required for detection of this potentially actionable oncogenic driver. Franco Fedeli, Serena Varesano, Sandra Salvi, Simona Boccardo, Mauro Truini, Paola Ferro, Pier Aldo Canessa, Maria Pia Pistillo, Silvio Roncella. ASL5, La Spezia, Italy; IRCCS A.O.U. San Martino-IST, Genova, Italy. Background: Malignant mesothelioma is an aggressive tumour, with poor prognosis and limited possibility of treatment. c-MET tyrosine-kinase was recently proposed for a targeted therapy and clinical trials with specific drugs, such as monoclonal antibodies or small-molecule tyrosinekinase inhibitors, are in progress in tumours characterized by the presence of c-MET deregulation. C-MET amplification leads to over-expression of its receptor expressed on the tumour cell membranes and identifies a subgroup of patients potentially able to respond to c-MET inhibitors. In contrast, it has been reported that c-MET amplification can represent an element of resistance for anti-EGFR inhibitor therapy.
Amplification of c-MET in Malignant Mesothelioma
The aim of this study was to analyze c-MET amplification and expression in mesothelioma.
Design: We analyzed paraffin-embedded tissues from 60 mesotheliomas (40 males and 20 females) in different stages and organ locations. FISH to evaluate c-MET gene amplification was performed by "Vysis MET Spectrum Red FISH Probe Kit" (Abbott Molecular Inc.). The samples with more than two c-MET gene hybridization spots in >10% of cell nucleos were considered amplified. Immunohistochemistry was performed using the "PATHWAY kit" by Benchmark XT system (Ventana Medical Systems Inc.) with "Met (C-12): sc-10" monoclonal antibody (Santa Cruz Biotechnology Inc.). Results: By previously described FISH methods, we evaluated the status of c-MET in 60 mesotheliomas (36 epithelioid, 12 sarcomatoid, 8 biphasic, 2 papillary and 2 desmoplastic types). We identified 4/60 (6.7 %) mesotheliomas with c-MET amplification. All amplified specimens were of epithelioid type and showed a high number (about ten) of specific hybridization spots in more than 80% of nucleos. Over-expression of c-MET receptor was found on the tumour cell membranes of all the amplified specimens.
Conclusions:
We report for the first time that, in a small proportion (about 7 %) of mesotheliomas, the amplification of c-MET was present and this amplification was associated with c-MET receptor over-expression. These preliminary observations may represent the basis for designing new clinical trials assessing c-MET targeting agents in mesotheliomas. Moreover, the possibility of c-MET amplification should be considered before starting treatments with the EGFR targeted inhibitors. Background: Neuroendocrine tumors (NET) of the lung comprise a heterogeneous group of neoplasms that exhibit a wide variation in clinical behavior. MicroRNAs (miRNAs) are short noncoding RNAs that bind to mRNAs and target them for downregulation/degradation. Aberrant expression of miRNAs has been shown to contribute to oncogenesis in many malignancies, but data on their expression in NETs of the lung were limited. In this study, we used small RNA sequencing to comprehensively examine miRNA expression profiles in these neoplasms. Design: Total RNA was extracted from formalin-fixed, paraffin-embedded tissue from typical carcinoids (TC, N=4), atypical carcinoids (AC, N=9), large cell neuroendocrine carcinomas (LCNEC, N=5) and small cell lung carcinomas (SCLC, N=5), and subjected to small RNA sequencing. NETs from other organs (N=52), i.e. pancreas, GI tract, adrenal and thyroid, were also profiled. Unsupervised clustering was performed using normalized data and mean miRNA expression levels were compared. Results: Unsupervised hierarchical clustering showed clean separation of carcinoids from SCLC based on their miRNA profiles. In contrast, TC and AC could not be clearly separated. LCNEC were more heterogeneous, and 4 of 5 cases clustered with SCLC but one with the carcinoid group. Comparisons between carcinoids and NECs showed the most significant difference to be the expression of 18 miRNAs clustered on chromosome 14q32. All 18 miRNAs showed lower expression in most (4/5) SCLC vs. carcinoids (p<0.001), 9 of them also downregulated in 4/5 LCNEC. Chr.14q32 contains the largest human miRNA cluster, and its downregulation has been described in various tumors but not in lung NECs. Of the non-pulmonary NETs that we profiled, pheochromocytoma also formed two subgroups that were separated by the differential expression of Chr14q32 miRNA cluster. Besides this cluster, putative tumor suppressor miR-129 (-3p and -5p) also showed lower expression in all 10 NEC (vs. carcinoids, p<0.001). Conversely, three miRNAs (miR-17, miR-20a, miR-21) were overexpressed in NECs (p<0.001), including miR-21 that has been shown to be overexpressed in multiple malignancies. Conclusions: Benign and malignant lung NETs can be separated based on their miRNA profiles, most significant differences being the downregulation of tumor suppressor miR-129 and the Chr14q32 miRNA cluster in most NECs but not in carcinoids. Chr14q32 miRNA status appears to separate lung NECs into two molecular subgroups, similar to our findings in pheochromocytomas.
EGFR Pathway Activation Via KRAS Mutation Leads To Cyclin D1 Expression and Decreased Proliferation in Lung Adenocarcinomas
Cora Hallas, Mia-Maria Warnke, Markus Tiemann. Institute for Haematopathology Hamburg, Hamburg, Germany; Semmelweis Universität Medizinische Fakultät, Hamburg, Germany. Background: The EGFR/RAS/RAF-pathway is implicated as a pathogenetic driver in at least a proportion of adenocarcinomas of the lung. Activation of this pathway may lead to transcriptional overexpression of Cyclin D1 via NFkB, but expression and functional role of this cell cycle regulator in lung adenocarcinomas has not been sufficiently evaluated.
Design: Proliferation (MIB-1, % positive cells), vascularization (CD34, number of blood vessels) and Cyclin D1 expression (positive or negative) was determined immunohistochemically in 141 adenocarcinomas of the lung and counted in in three representative high power fields (HPF) each. (TSC) genes and consequent hyperactivation of the mammalian target of rapamycin complex 1 (mTORC1) signaling, which lead to formation of pulmonary cysts. Clinically, the most common abnormalities of pulmonary function tests in LAM patients are airflow obstruction. Also, activation of mTORC1 in tumor cells results in the accumulation of hypoxia inducible factor 1 alpha (HIF-1α), and increases expression of HIF-responsive genes including vascular endothelial growth factor (VEGF). However, neither histopathology of airways nor expression of HIF-1α has not to be fully characterized in LAM patient's tissues.
Design:
We examined histological analysis of explanted lung tissues in 30 LAM patients with special emphasis on airways. We further examined immunohistochemistry, RT-PCR, and western blot analyses focusing on mTORC1 signaling, HIF-1α, and vascular endothelial growth factor (VEGF)-D expression in LAM tissues.
Results:
The results showed that destruction of airway walls caused by proliferation of LAM cells or lymphatic vessels was identified in all patients examined. Additionally, chronic inflammation in airways at a moderate level or higher was identified in 22 patients. Expression of phospho-p70S6K, phospho-S6, phospho-4E-BP1, and VEGF-D was found in all patients examined; when stratified according to staining grade (scale 0-3), average score in LAM lesions was 2.9 for phospho-p70S6K, 2.7 for phospho-S6, 2.2 for phospho-4E-BP1, and 2.5 for VEGF-D. In contrast, no expression of HIF-1α was detected in any patients.
Conclusions:
These results indicate that destruction of airways caused by proliferation of LAM cells or lymphatics, accompanied by chronic inflammation is a common manifestation of patients with advanced stage of LAM. Furthermore, activation of mTORC1 does not result in upregulation of HIF-1α in LAM cells; this feature may distinguish LAM from other common tumors that have constitutive activation of mTORC1 signaling. We examined the distribution of KRAS mutation subtypes using the Catalogue Of Somatic Mutations In Cancer (COSMIC) database for colon, lung and pancreatic adenocarcinomas. To determine the contribution of mutational biases for each tumor type, we used data of synonymous mutations occurring within tumors of these types within the Cancer Genome Atlas (TCGA) database. Using these data we were able to normalize the actual KRAS mutation subtype distribution to the expected base pair changes and determine the relative selective power of each mutation. We then examined a sample set of 100 KRAS positive lung adenocarcinoma cases and correlated mutation subtype with clinico-pathological information.
Results: KRAS mutation subtype distribution was significantly different between the tumor types with c.35G>A presenting 35%, 17% and 51% of KRAS mutations in colon, lung and pancreatic adenocarcinoma, respectively (p<0.0001). Following normalization to the TCGA data, p.G12A and p.G12V were the most positively selected mutations in colon carcinoma and p.G12C was the most positively selected mutation in lung adenocarcinoma. In our lung adenocarcinoma data set the evolutionary selected, p.G12C Results: 473 total lung cancers were analyzed for NKX2-1 mutations. Of these, 33 cases were diagnosed as mucinous adenocarcinomas, while an additional 20 cases had mucinous features on histology. Five cases of lung adenocarcinoma were identified that harbored NKX2-1 frameshift mutations predicted to cause NKX2-1 loss of function. All cases had a concurrent KRAS codon 12 mutation. Histological review showed that four of the cases were pure invasive mucinous adenocarcinoma, and one case was a mixed mucinous and non-mucinous adenocarcinoma. Of four cases with available NKX2-1 immunohistochemistry, three cases were negative for NKX2-1, and one case exhibited focal staining. NKX2-1 frameshift mutations were not identified in non-mucinous lung adenocarcinomas and carcinomas of gastrointestinal origin.
We report the first observation of recurrent somatic loss of function mutations involving NKX2-1 in lung adenocarcinoma. These neoplasms have distinct features, including mucinous differentiation and concurrent mutations in KRAS. This association supports a role of NKX2-1 as a putative tumor suppressor gene in the pathogenesis of human mucinous lung adenocarcinoma. Detection of NKX2-1 mutations may be helpful to distinguish a primary lung adenocarcinoma from metastasis in the context of ambiguous immunohistochemical results.
Global Mutational Profiling and Comparative Analysis With Histomorphologic Features in Female Never-Smoker Lung Adenocarcinoma Soo Hyun Hwang, Sang Yun Ha, Jhingook Kim, Yoon-La Choi. Samsung Medical
Center, Seoul, Republic of Korea. Background: The aim of this study was to determine the distribution of known oncogenic driver mutations in female never-smoker Asian patients with lung adenocarcinoma. Design: We analyzed 214 mutations across 26 lung cancer-associated genes and three fusion genes using the MassARRAY® LungCarta Panel and ALK, ROS1, and RET fusion assay in 198 consecutively resected lung adenocarcinomas from never-smoker females at a single institution. Results: EGFR mutation was the most frequent driver gene mutation and was found in 124 (63%) cases. Mutation of ALK, KRAS, PIK3CA, TP53, ERBB2, BRAF, ROS1, and RET was observed in 7%, 4%, 2.5%, 2%, 1.5%, 1%, 1%, and 1%, respectively. Thus, 79% of lung adenocarcinomas from never-smoker females were found to harbor wellknown oncogenic mutations. Mucinous adenocarcinoma had a tendency towards a lower frequency of known driver gene mutations compared with other histologic subtypes. EGFR mutation was positively correlated with older age and acinar-predominant pattern.
ALK rearrangement was associated with younger age and solid predominant pattern. Conclusions: Lung cancer in never-smoker Asian females is a distinct entity, with the majority of these cancers developing from oncogenic mutations. Prospective studies of driver mutation status in this subpopulation will be helpful in devising targeted therapies that will benefit many lung cancer patients. Background: Thymoma pathogenesis is poorly understood. To-date, no specific oncogene or tumor suppressor mutations have been identified in these tumors. We investigated the role of some well-known oncogenes and transcription factors by using immunohistochemistry to determine the expression levels of known oncogenes (MDM2, ROS, ALK1, and c-Met) and tumor suppressors (PTEN, p53). Background: PAX-8 transcription factor is normally expressed in the kidney, thyroid and cervix. Multiple previous studies have described PAX-8 positivity in thymomas and the PAX-8 immunohistochemistry has been proposed and used as an adjunct marker of thymomas. However, with the advent of monoclonal PAX-8 antibodies it became apparent that many of the previous reports of PAX-8 positivity in other epithelial tumours were due to a cross-reactivity of the polyclonal antibodies to PAX-8 with the N-terminal regions of PAX-5 and / or PAX-6. We have therefore decided to retest PAX-8 immunohistochemistry in thymomas using a new monoclonal PAX-8 antibody.
Design: Review of British Columbia Cancer Agency files from 1995 to 2008 identified 174 thymomas and thymic carcinomas. Blocks were available for eighty three surgical specimens. One case represents a recurrence. Tissue microarray (TMA) was constructed using duplicate 1.0 cm cores from the representative areas of each tumor. Among the 83 cases, there were 6 WHO class A tumours, 9 AB tumors, 18 B1 tumors, 31 B2 tumors, 15 B3 tumors and 5 thymic carcinomas. One case had separate areas of B2 thymoma and adenosquamous thymic carcinoma, both of which were included, for a total of 84 samples. The TMA was stained with PAX-8 mouse monoclonal antibody (BC-12, Biocare Medical), PAX-5 mouse monoclonal (24, Cell Marque), PAX-6 mouse monoclonal (SC-81649, Santa Cruz), as well as control stains with pankeratin cocktail (composed of AE1/AE3, MNF116, 5D3, and CAM5.2) and hematoxylin and eosin. Staining was graded as 0 (staining in < 1% of tumor cells), 1+ (1-25%), 2+ (26-50%), 3+ (51-75%), and 4+ (76-100%).
Results: None of the eighty four thymomas and thymic carcinomas showed any detectable PAX-8 staining. Positive PAX-5 staining (1+ to 4+) was detected in 5 of 84 tumors (6%). Positive PAX-6 staining (1+ to 4+) was detected in 15 tumors (18%), however only 5 tumors (6%) showed staining in more than 25% of cells (2+ or higher). Three of those five tumours also had PAX-5 positivity. All samples showed pankeratin cocktail positivity. Conclusions: Thymomas and thymic carcinomas do not express PAX-8. Previous reports of PAX-8 positivity in thymomas may be the result of cross-reactivity of the polyclonal PAX-8 antibodies with either PAX-5 or PAX-6. Therefore PAX-8 should no longer be used in the identification of thymomas and thymic carcinoma in clinical practice. Background: Transbronchial lung transplant biopsies are routinely evaluated for acute and chronic rejection. Acute rejection is defined as characteristic perivascular mixed inflammatory cell infiltrate (graded from A0-A4), and/or lymphocytic bronchiolitis (graded from B0-B4, 1996 grading scheme). The grading system is based on presence or absence of inflammatory infiltrate and its intensity and localization. While most cases of acute rejection can be easily recognized, occasionally it may be difficult to distinguish perivascular/peribronchiolar infiltrate from bronchus-associated lymphoid tissue (BALT). BALT is part of the lung immune system that consists of well-circumscribed, small aggregates of lymphoid cells in the submucosa/wall of the airways and along the lymphatic routes. BALT is usually composed of a central vessel with prominent epithelioid endothelial cells surrounded by mixture of follicular center cells with small lymphocytes and plasma cells at the periphery of the aggregate. Design: The goal of the study was to determine if the presence of CD21 positive follicular dendritic cells could distinguish acute rejection from BALT. 75 cases of transbronchial lung transplant biopsies containing rejection and/or one or more BALTs were selected. CD21 antibody was used to evaluate 20 rejections and 63 BALTs for presence or absence of follicular dendritic cells. To evaluate statistical significance the categorical data was analyzed using a Fisher's exact test due to uneven contingency table distribution. Significance was defined as P-Value < 0.05. Results: All 20 biopsies with acute rejection were negative for CD21 (0% positive) while 46 of 63 BALTs (73%) were positive for CD21, a significant difference (P-value<0.0001) and 17 were negative (27%).
Expression of Met in Circulating Tumor
Conclusions:
In lung transplant biopsies in which the perivascular/peribronchiolar inflammatory infiltrate is difficult to distinguish from the BALT, CD21 antibody may be helpful as it detects follicular dendritic cells in 3/4 of BALTs. Background: Invasion in lung cancer is traditionally defined by tumor growing into stroma, pleura or blood vessels. We have identified a novel pattern of invasion in LAdc where tumor cells spread through alveolar spaces (STAS). This is a pattern not seen in other organ systems because of the unique anatomy of the airspaces in the lung. We investigated whether STAS correlated with a risk of recurrence according to types of surgery (limited and anatomical resection) and locations of recurrence (locoregional and distant). Design: We reviewed resected small (≤ 2cm) stage I LAdc (n = 411; 1995-2006) . Tumor STAS was defined as isolated tumor cells within alveolar spaces separate from the main tumor, and was composed of 3 morphological patterns: micropapillary structures, solid nests, and single cells. Differences in recurrence-free probability (RFP) between groups were examined using logrank test. Multivariate analyses were performed using Cox proportional hazards regression.
Results: STAS was observed in 155 cases (38%). In limited resection group (n = 120), the RFP for any recurrence of patients with STAS-positive tumors was significantly lower than STAS-negative tumors (5-year RFP, 52% vs. 88%; P < 0.001; Tumors, classified according to WHO and staged using TNM, were stained with CK5/6 and/or p40 antibodies. EBV-encoded DNA was detected by in situ hybridization (ISH). Results: Findings of 37 pts with TCa are summarized in Table 1 . EBV-ISH was positive in 3 cases (8.1%) who presented with chest pain (n=3), shortness of breath (n=2), weight loss (n=1), cough (n=1) and/or back pain since childbirth (n=1). The tumors were of moderate (n=1) or poorly (n=2) differentiated morphology. All underwent neoadjuvant and/or adjuvant therapy. Background: Restrictive Allograft Syndrome (RAS) has recently been described as a specific from of chronic lung allograft dysfunction (CLAD), characterized functionally by restrictive ventilatory deficits, and histologically by a constellation of features including pleuroparenchymal fibroelastosis and interstitial fibrosis. RAS is commonly preceded by acute lung injury, which may often be seen in post-transplant transbronchial lung biopsies (PTxTBLB) of patients developing RAS. However, the frequency with which features diagnostic of RAS may be identified in PTxTBLB is not known. We therefore reviewed PTxTBLB of patients with RAS, to characterize the presence of parenchymal fibroelastosis and other forms of fibrosis in these samples. Design: We retrospectively reviewed PTxTBLB specimens from 13 patients with histologically confirmed RAS, transplanted at our institution between March 2003 and June 2011. Thirty-eight controls PTxTBLB matched for time post-transplant were also reviewed. The H&E and elastic trichrome slides of all specimens were assessed for histologic patterns of lung parenchymal fibrosis. All slides were reviewed by two pathologists with pulmonary expertise. Results: A total of 41 PTxTBLB from 13 RAS patients were available for review. Of these, 5 cases from 5 patients demonstrated features of parenchymal fibroelastosis, characterized by patchy but confluent deposition of hypocellular collagen with marked thickening alveolar septae. Nine cases demonstrated focal intra-alveolar organizing fibrosis, and 9 cases demonstrated interstitial/septal fibrosis with a non-specific appearance and 6 cases demonstrating both patterns of fibrosis. The majority of PTxTBLB (29/41) showed at least one pattern of fibrosis. We found no parenchymal fibrosis in the controls but two control cases showed focal peribronchial fibrosis with features suggestive of previous biopsy sites. Conclusions: Features of pleuroparenchymal fibroelastosis and lung parenchymal fibrosis are frequently present in the PTxTBLB of patients who develop RAS. Further studies to assess the significance of fibrosis in PTxTBLB are warranted. Clinical and pathological data including stage at time of diagnosis, survival, histologic subtype, age, smoking status and therapy were retrieved from the electronic medical record and tabulated. Results: A total of 40 patient samples from 20 men and 20 women, 50-90 years of age (average 66.5 years) were analyzed. Of these 40 patients, 22 are deceased with survival times ranging from 0.5-21 months (average 5.5 months) and three were lost to follow-up. All but one patient had a smoking history with reported pack-years ranging from 5 to 105 (median 40 pack-years). Exon mutations were identified in TP53 (18), KRAS (13), All three patients are alive 33, 31 and 3 months after transplant, respectively. Interestingly, repeated post-transplant biopsies showed recurrence of GIP in patient 1. Conclusions: All three patients had relatively nonspecific occupational histories and only one patient had a detectable cobalt level in the lung tissue. These findings suggest that GIP is not limited to patients with hard metal exposure and other environmental exposures may lead to the same histologic pattern.
Architectural Differences Between Typical and Atypical Carcinoids of the Lung and Their Prognostic Significance
Ihab Lamzabi, Lauren Rosen, Richa Jain, Aparna Harbhajanka, Sahr Syed, Vijaya Reddy, Paolo Gattuso. Rush University Medical Center, Chicago, IL. Background: Well differentiated pulmonary neuroendocrine tumors (NETs) consist of typical (TC) and atypical carcinoid (AC). They are subdivided by World Health Organization (WHO) based on mitoses and necrosis into grade 1 (TC) and grade 2 (AC). However, 10 to 20% of patients with TC die of disease within 5 years and literature regarding the histologic characteristics of these "high-risk" well-differentiated NETs is limited. To improve our recognition of higher risk subgroups of TC and AC, we therefore investigated a cohort of cases using objective and thorough histologic criteria. Design: We searched our electronic surgical pathology records to identify cases of TC and AC. Only resection specimens, tumors larger than 0.5 cm and cases with available H&E slides were included. The H&E slides were blindly reviewed separately by 2 pathologists for an exhaustive list of histologic features. Mechanisms of acquired or de novo resistance to TKI mainly involve T790M mutation, C-Met amplification or AXL activation. Objective of this study is to evaluate the sensitivity and specificity of antibodies targeting specifically EGFR mutations, and to determine if T790M mutation, C-Met or AXL overexpressions before treatment could predict TKI response or resistance. Design: EGFR, C-Met and AXL expressions were compared by immunohistochemistry in 40 tumors exon 19 deleted and in 29 tumors mutated exon 21, with 48 adenocarcinomas EGFR wild-type. For EGFR antibodies, tumors were considered as positive when more than 10% of the cells were positive. For C-Met and AXL, high scores (≥ 50% positive cells 2 and 3 + intensity) were considered as positive. Mutations were detected by pyrosequencing. Results: Sensitivities of the EGFR exon 19 mutant-specific antibody and EGFR exon 21 mutant specific antibody were 75% and 86%, respectively; both specificities were of 93.5%. High levels of C-Met expression were observed in 35% of exon 21 mutated EGFR cases (10/29), and in 25% of exon 19 EGFR deleted cases (10/40); the frequency of AXL high expression was the same in both groups (31% and 32%). Among the 23 patients TKI treated, for one patient with complete response, no T790M mutation, C-Met hyperexpression or AXL expression was observed; for 5 patients with stable diseases, a high AXL expression was observed in 2 tumors; in contrast, for patients with partial response (n=11) or progression (n=6), T790M mutation was observed in 5 cases, C-Met overexpression in 5 cases and high AXL expression in 5 cases. Overall, T790M mutation, C-Met hyperexpression or AXL expressions were observed in 71% patients with partial response or progression, and were mutually exclusive except for 2 patients. Conclusions: EGFR antibodies offer a good specificity but a low sensitivity, and cannot serve as a routine diagnostic tool. In contrast, de novo T790M mutation, or high levels of C-Met or AXL expression can contribute to predict a partial TKI response or progression. . Genetic changes were found in 5 (42%) of cases. EWSR1 rearrangements were seen in 3 cases (25%, 2 MCs and 1 ME). EWSR1-ZNF444 and EWSR1-PBX1 fusion genes were identified in the 2 MCs. An FUS rearrangement was identified in one ME (8.3%). The one case of MCAC showed HMGA2 amplification, while no PLAG1 abnormalities were detected. Conclusions: LMTs show a wide histologic spectrum and frequently have characteristic genetic features. While elevated mitotic activity might be an indicator of high grade lesions, cytologic atypia and necrosis appear to be more reliable predictors of malignancy. Similar to soft tissue, LMTs lack encapsulation and, of the 42% of cases with molecular aberrations, the majority had EWSR1 and FUS abnormalities. The only case with HMGA2 amplification, typically associated with salivary gland origin, occurred in combination with adenocarcinoma, which might represent a histologically and molecularly distinct type of LMTs. While the clinical significance of these molecular signatures has yet to be determined, they are novel ancillary markers in the challenging diagnosis of LMT. Background: Histologic subtyping of lung adenocarcinoma, particularly identification of a predominant pattern, is currently recommended. Reproducibility has been previously comprehensively studied using photomicrographic images (Thunnissen E et al, Mod Pathol 2012), however there are still only limited data on reproducibility in complete clinical cases consisting of multiple slides (Warth A et al, Eur Respir J 2012; Wells JM et al, Mod Pathol suppl 2012) . Design: All tumor slides (average 5, range 2-10) from 20 consecutive prospectivelyencountered resected adenocarcinomas were reviewed by 6 pathologists with experience in lung pathology. For each case, reviewers assigned a percentage, in increments of 5%, of the following 6 patterns: lepidic, acinar, papillary, micropapillary, cribriform, and solid, and selected a single predominant pattern. Results: The number of patterns identified per case averaged 3.9 (range 2-6). Complete agreement among 6 reviewers on a predominant pattern was achieved in 4/20 (20%) cases, and 5 of 6 reviewers agreed in 10/20 (50%) cases. In pairwise comparison, agreement on predominant pattern between 2 reviewers ranged from 35-75%. On average, predominant pattern exceeded other patterns by 29%, but in 30% of scores this difference was <10%. In cases with complete agreement, the amount of predominant pattern exceeded other patterns by an average of 46%, compared to an average of 25% in cases without complete agreement (P<0.
Malignant Pleural Mesothelioma in Children and
0001). There was no difference in the average number of slides for cases with or without complete agreement (5.5 vs 5.6, respectively; P=0.865). Overall, there was greater variability in quantitation of acinar, papillary and micropapillary than lepidic, cribriform and solid patterns (P=0.0007).
Conclusions:
Lung adenocarcinomas are highly heterogeneous histologically, as reflected by the high number of patterns identified per case. We find that close codominance of more than one pattern may occur in up to one third of cases, and this feature correlates with low reproducibility in selecting a single predominant pattern among reviewers. On the other hand, the wide range of agreement in pairwise comparison and the variability in quantifying patterns suggests that further refining the morphologic definitions and group training sessions could improve reproducibility. Background: Organizing pneumonia (OP) has many causes, and may plug bronchioles (bronchiolitis obliterans organizing pneumonia, BOOP) or have no apparent association with airways. The use of the terms "BOOP," "idiopathic BOOP," "OP," and "cryptogenic organizing pneumonia" (COP) is not completely standardized. We undertook a retrospective study to determine the frequency of bronchiolocentric v. interstitial organizing pneumonia with emphasis on underlying associations.
Design: 40 open biopsies over a 12-year period with the diagnosis of "organizing pneumonia" were retrospectively reviewed. Clinical data, including pulmonary function tests, follow-up, serologic tests, and thoracic computed tomographic imaging were collected, resulting in 3 clinical groups: idiopathic (cryptogenic) organizing pneumonia (I-OP), organizing pneumonia associated with autoimmune diseases (A-OP), and presumed post-infections organizing pneumonia (P-OP). Independently, the numbers of loose fibroblastic nodules, distribution of OP (interstitial only, predominantly interstitial, and predominantly bronchiolocentric with luminal plugs), and extent of bronchiolar inflammation were semiquantitated without knowledge of clinical grouping. Results: There were 15 cases of I-OP, 14 cases of A-OP, and 11 cases of post-infectious OP. Autoimmune diseases included undifferentiated connective tissue disease (n=6), rheumatoid arthritis (n=2), dermatomyositis (n=3), granulomatous polyangiitis (n=1), scleroderma / polymyositis (n=1), Crohn's disease (n=1). 17 patients were women and 23 men, with a mean age of 54; A-OP and post-infectious OP were younger than I-OP patients (p=0.04). There were 15 biopsies with only interstitial OP, 22 with predominantly interstitial OP, and 3 with predominant bronchiolar plugs. There was no significant difference in the numbers of nodules across groups. There was a positive association between bronchiolar location and patients with autoimmune disease (p=.01). Bronchiolitis and peribronchiolar metaplasia were more extensive in A-OP than I-OP and post-infectious OP (p=0.02). Conclusions: Bronchiolocentric OP and bronchiolar inflammation is relatively extensive in OP associated with autoimmune disease. It may be useful to maintaining separate designations for "BOOP" and "OP" as the rate of underlying diseases differs. Design: Rabbits were immunized with EGFR L858R peptide. Sera collected from immunized rabbits were screened by ELISA, WB and IHC. Hybridoma was generated by fusing splenocytes with the fusion partner cell line (240E-W2). Antibody from final hybridoma cell line was further characterized by extensive IHC testing using formalin fixed paraffin embedded (FFPE) human normal, tumor and EGFR L858R mutant tumor tissues. EGFR L858R gene mutation was detected by FemtoPath (Patent No. P2708-TW) or Sanger dideoxy sequencing (ABI 3730) mutation analysis. The concordance of EP344 IHC staining results with mutation status was analyzed and compared against EGFR L858R rabbit monoclones SP125 and 43B2. Results: A 175 KDa EGFR L858R protein was detected by WB in EGFR L858R mutant H1975 cells, but not in wild type cells. IHC analysis of EP344, SP125 and 43B2 on human tissue microarray (TMA) comprising 16 types of normal tissues showed that all 3 antibodies stained negatively in all normal cells. In two tumor TMAs comprise of 16 types of tumors showed that 3 in 16 lung adenocarcinomas and 2 in 21 lung squamous carcinomas are positive with all 3 antibodies. EP344 is negative in all other tumors, while SP125 and 43B2 positive staining was found in breast carcinoma with EGFR wild type. Furthermore, a separate group of 13 lung carcinomas with EGFR L858R mutation was stained with all antibodies. We found that the concordance of EP344, SP125 and 43B2 staining results with mutation status was 92.3%, 77% and 23% respectively. Conclusions: RabMAbs anti-EGFR L858R, clone EP344 is specific and sensitive in the detection of target mutant proteins by IHC in FFPE tissues. EP344 is highly concordant with EGFR L858R mutation status. Comparing to current EGFR L858R antibodies, EP344 may be a potentially better tool for predicting EGFR L858R mutation status by IHC testing. Results: We showed that PHLDA2 as a robustly induced, novel downstream target of oncogenic EGFR/ErbB2 signaling. The level of PHLDA2 protein expression correlates positively with AKT activation in human lung cancers (correlation coefficient=0.336, p=0.0002) corroborating our data that PHLDA2 is induced upon oncogenic activation and might serve as a biomarker for AKT pathway activation. We also showed that PHLDA2 overexpression inhibits AKT phosphorylation while decreased PHLDA2 expression mediated by siRNA interference increases AKT activity. In further studies we find that PHLDA2 competes with the PH domain of AKT for binding of membrane lipids, thereby directly inhibiting AKT translocation to the cellular membrane and subsequent activation. Indeed, PHLDA2 overexpression suppresses anchorage-independent cell growth and decreased PHLDA2 expression results in increased cell proliferation and reduced sensitivity to targeted agents of EGFR/ErbB2-driven cancers demonstrating functional relevance for this interaction. Conclusions: PHLDA2 expression is immediately and strongly regulated by EGFR/ ErbB2 signaling and inhibits cell proliferation via repressing AKT activation in lung cancers in a negative feedback loop. Our studies demonstrate a novel action for PHLDA2 as an AKT inhibitor with translational implications and highlight PHLDA2 expression as a potential biomarker for AKT pathway activation. Fudan University Shanghai Cancer Center, Shanghai, China; Cleveland Clinic, Cleveland, OH. Background: The incidence and significance of psammoma bodies in lung adenocarcinomas is unknown. Recent studies have reported a high incidence of psammoma bodies in tumors with ALK, ROS1 or RET fusions. The aim of this study was to determine the incidence of psammoma bodies in lung adenocarcinomas, and examine their association with histologic patterns and oncogenic drivers. Design: Comprehensive histologic subtyping of 648 resected lung adenocarcinomas (United States 364, China 284) was performed. The presence of psammoma bodies was noted, and the predominant histologic pattern was recorded. All cases from China had been tested for EGFR, ALK, KRAS, ROS1 and RET. They included 48 fusion-positive (23 ALK-pos, 9 ROS1-pos, 16 RET-pos) tumors and 230 fusion-negative tumors (27 EGFR-pos, 20 KRAS-pos, 183 pan-negative). The incidence of psammoma bodies in fusion-positive and fusion-negative adenocarcinomas was compared. Results: The incidence of psammoma bodies in resected lung adenocarcinoma was 7% in the US cases (27/366) and 17% in China (46/278). In the 27 US cases with psammoma bodies, the predominant histologic patterns were acinar (13), micropapillary (12), solid (1) and lepidic (1). Most (25/27) had a micropapillary component. In the 46 Chinese cases with psammoma bodies, the predominant histologic patterns were acinar (23), micropapillary (9), mucinous (6), solid (5), papillary (2) and lepidic (1); most (38/46) had a micropapillary component. Psammoma bodies were more common in tumors with any micropapillary component than in tumors lacking a micropapillary component (p<0.001). In the Chinese cases, psammoma bodies were found in tumors positive for ALK (13/23, 57%), ROS1 (3/9, 33%), RET (8/16, 50%), EGFR (5/27, 19%) and KRAS (1/20, 5%), and were uncommon in pan-negative tumors (16/183, 9%). Lung adenocarcinomas with psammoma bodies were significantly more likely to contain a mutation or fusion (p<0.0001), and significantly more likely to be fusionpositive (ALK-pos/ROS1-pos/RET-pos) than fusion negative (EGFR-pos/KRAS-pos/ pan-neg) (p<0.001).
1935
PHLDA2 Is a Key
Oncogene-Induced Negative Feedback Inhibitor of EGFR/ErbB2 Signaling Via Interference With AKT Signaling Guangyuan Li, Xiaoqi Wang, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos. University Hospitals of Case Medical Center, Cleveland
Conclusions:
The incidence of psammoma bodies in lung adenocarcinomas is 7-17%, and is higher in China than the United States. Most lung adenocarcinomas with psammoma bodies have a micropapillary component, and are likely to harbor an oncogenic driver mutation or translocation. There is a strong association between psammoma bodies and oncogenic fusions (ALK/ROS1/RET). 
Distribution of p40 and TTF-1 Expression in Lung Adenocarcinomas
adenocarcinoma with focal cribriform areas (diagnosis based on architecture, group A); adenocarcinoma with scattered mucin vacuoles without cribriform growth (group B); and solid adenocarcinoma without cribriform areas or mucin vacuoles, with TTF-1 expression (group C). Potential misdiagnosis on limited sampling was determined if there were significant areas of discordance of TTF-1 and p40 expression. Results: There were 19 group A, 12 group B, and 10 group C tumors. Of group C tumors, 4 showed squamoid features, 2 had prominent desmoplasia, 2 rhabdoid features, and 2 prominent nested pattern. The mean percentages of TTF-1 positive cells in group A, B, and C were 81.8%, 32.1%, and 60.5% respectively (p=0.0026, ANOVA). 31 tumors were negative for p40 (85%); of these, 12 (29%) showed TTF-1 staining in ≤ 50% of tumor cells. Of these 12, diagnosis of adenocarcinoma was made on focal TTF-1 staining in 5, and focal mucin vacuoles in 7; none showed cribriform growth. 6 tumors expressed p40; of these, 2 showed discordant staining, with approximate equal staining of both antigen; 2 showed very focal p40 staining, and 2 showed concordant TTF-1 and p40 staining. Conclusions: Based on extent of TTF-1 and p 40 staining, 5 tumors in this series may have been diagnosed on biopsy as non-small cell, NOS, because of focal TTF-1 stainin, and 2 may have been misdiagnosed as squamous based on sampling of p40 positive and TTF-1 negative areas. Therefore, the rate of imprecise diagnosis of non-small cell carcinomas could have been as high as 12% (missing TTF-1 positive areas) and incorrect diagnosis of squamous carcinoma in up to 5% (discordant staining). 17% would have required the finding of intracytoplasmic mucin vacuoles. These findings suggest a low rate of misdiagnosis (5%) if p40, TTF-1 and mucin staining is performed on small biopsy samples of lung carcinomas with solid growth. Immuno-therapeutic approaches targeting PD-1 or its primary ligand, PD-L1, and their predictive biomarkers, such as tumor PD-L1expression are of great interest. Previous human studies and mouse model data suggest a high expression of PD-L1 in MMs. In addition, it is suggested that PD-L1 expression could be linked to the quantity of tumor infiltrative lymphocytes (TILs). Herein we investigated PD-L1 expression in a series of lymphohistiocytioid malignant mesotheliomas (LHMMs) compared to conventional malignant mesothelioma types(CMMs), and its relationship with the number of TILs and their PD-1 expression. Design: 64 formalin-fixed paraffin-embedded (FFPE) pleural MMs were retrieved from the MESOPATH files. Twenty nine LHMMs and 35 CMMs (28 epithelioid, 6 biphasic, and 1 Sarcomatoid) were strictly ascertained according to the French standardized certification. PD-L1 (3F2.1) and PD-1 (NAT) expressions were evaluated immunohistochemically. According to previous studies PD-L1 positivity was considered when ≥5% membrane cell staining was observed. PD1 expression in TILs was evaluated by percent of cytoplasmic positive staining on lymphocytes within the tumor. TILs quantity was scored from 0 to 3 by quarters of 25% of cells within the tumor. Results: A total of 69% (44/64) cases were positive for PD-L1. LHMMs tended to be less PD-L1 positive (17/29; 59%) than CMMs (27/35; 77%) (p=0.11). Surprisingly, PDL1 positive MMs had a better overall survival at 2 years, confirmed in multivariate analysis (adjusted for histologic type, age, and necrosis) with 2 times less risks of death for PD-L1 positive patients (RR adjusted =0.4; IC [0.212-0.769]). PD-L1 had a tendency to be less expressed in TILs rich tumors. PD-1 was more expressed in PD-L1 positive tumors (p=0,005) with a negative predictive value of PD-L1 for PD-1 of 100% (9/9), and a positive predictive value of 54% (14/26). Conclusions: MMs have a high rate of PD-L1 expression (69%). Unexpectedly, LHMMs are less often positive for PD-L1 than CMMs (59% vs 77%). Moreover, in our series, PDL1 positive MMs have a better survival at 2 years, both in uni and multivariate analysis (RR adjusted=0.4; p=0.0058). Consequently, additional studies are mandatory for a better understanding of the PD-1/PD-L1 and TILs mechanisms in MMs and their type and subtypes. Whatever MMs could be of great interest for anti PD-1/PD-L1 therapies.
Expression of Programmed Death Ligand-1 (PD-L1) and T-Cell Populations in Neoplastic and Non-Neoplastic Thymus
Alberto Marchevsky, Beatrice Knudsen, Steven Swartwood, Ann Walts. Cedars-Sinai Medical Center, Los Angeles, CA. Background: PD-L1 inhibits activated T-cells by binding to its receptor, PD-1, on the surface of activated T-cells. The ability of tumor cells to express ligands for programmed cell death protein-1, primarily PD-L1, downregulates immunoregulation helping tumors avoid detection and allowing for tumor growth, progression, and/or metastases. Therapeutic antibodies that block the PD-1 immune checkpoint promote immune responses against tumors. Expression of PD-L1 has not been previously reported in neoplastic and non-neoplastic thymus. Design: 12 non-neoplastic thymus, 7 thymomas (classified per WHO as 1 AB, 3 B2, 3 B3), and 3 thymic squamous carcinomas were selected from our pathology database. Selected slides were immunostained using PD-L1 antibody (clone E1L3N; Cell Signaling, Danvers MA). 17 of the 22 cases were stained by multiplex immunohistochemistry using antibodies directed against PD-L1, CD4, and CD8 (SP35 and SP57, respectively; Ventana, Tucson AZ). Any immunoreactivity was recorded as positive. The percentage of cases positive for each antibody was recorded. Results: PD-L1 immunoreactivity was observed in 3 (25%) of 12 non-neoplastic thymus, 5 of 7 thymomas, and 3 of 3 (100%) thymic squamous carcinomas. Non-neoplastic thymus showed a predominance of CD4+ T-cells in the cortex and predominance of CD8+ T-cells in medullary areas. In 4 of the 5 PD-L1-positive thymomas and all 3 PD-L1-positive carcinomas a predominance of CD4+ T-cells was observed. One AB thymoma showed a predominance of CD8+ T-cells in the spindle cell component. Conclusions: -PD-L1 is expressed in 25% non-neoplastic thymus.
-PD-L1 is expressed in >70% of thymomas and thymic squamous carcinomas. -Additional studies quantifying expression of PD-L1, PD-1 and T-cell subsets in these neoplasms by digital image analysis are needed to determine whether the PD-L1/PD-1 pathway is a potential therapeutic target for the treatment of advanced thymic neoplasms.
Pathological Role of Fibroblastic Foci and Bronchiolar Epithelial Proliferation in Idiopathic Pulmonary Fibrosis (IPF)/Usual Interstitial Pneumonia (UIP)
Osamu Matsubara, Yuichi Ishikawa, Yukio Nakatani, Eugene Mark. The Cancer Institute, Tokyo, Japan; Hiratsuka Kyosai Hospital, Hiratsuka, Japan; Chiba University, Chiba, Japan; Massachusetts General Hospital and Harvard Medical School, Boston, MA. Background: Characteristic features of IPF / UIP on histology include patchy interstitial fibrosis, active fibroblastic foci (FF), and surrounding bronchiolar epithelial proliferation (BEP). FF consist of a loose myxoid stroma and active fibroblasts and myofibroblasts which open nuclei and covered by pneumocytes or respiratory epithelial cells, and would seem to be as the sites where fibrotic responses and acute exacerbation events are initiated. Previous studies suggest that increased FF signify a worse prognosis and faster disease progression. Design: We investigated the cellular and molecular profile of FF and bronchiolar epithelial proliferation in 27 video-assisted thoracoscopic biopsies (VATS) of IPF/UIP with 5 patients who had acute exacerbation later and a variety of control lung samples, focusing on the immunohistochemical expression of the molecules involved in FF and cellular proliferation, namely alpha-SMA, vimentin, desmin, TGF-beta1, CTGF, VEGF, E-cadherin, beta-catenin, TTF-1, napsin A, Ki-67, PCNA, cyclin D1, MMPs and TIMPs. We used a standard indirect avidin-biotin horseradish peroxidase method with various antigen retrievals. Apoptotic DNA strand break by nick end-labeling technique (TUNEL) was also examined. Results: The spindle cells in FF expressed alpha-SMA, vimentin, as well as TGF-beta 1, CTGF and VEGF, but only faintly MMPs and TIMPs. The covering epithelium expressed TGF-beta 1 and CTGF and partially TTF-1 but had diminished expression of E-cadherin and beta-catenin. There was increased staining of Ki-67, PCNA and cyclin D1 in fibrotic cells, pneumocytes and bronchiolar cells. Apoptotic cells were not detected. There were no significant differences in the frequency of FF and the degree of BEP between the patients with and without later acute exacerbation, but more extensive accumulation of alveolar macrophages was seen in the patients with later acute exacerbation. Conclusions: Up-regulation of markers of cell proliferation in both mesenchymal and epithelial cells at sites of FF is consistent with remodeling of lung in UIP/IPF at these sites. Overexpression of various growth factors may cause the exaggerated and proliferative character of the fibroblasts/myofibroblasts and bronchiolar epithelium that leads to architectural simplification and honeycomb fibrosis. Acute exacerbation initiation might not be related to FF lesions.
BAP1 Loss Portends Improved Prognosis in Malignant Pleural Mesothelioma Due To Frequent Association With Epithelioid Morphology
Stephanie McGregor, Ryan Dunning, Duraid Hadi, Wickii Vigneswaran, Aliya Husain, Thomas Krausz. University of Chicago Hospitals, Chicago, IL. Background: BAP1 (BRCA-associated protein 1) is a tumor suppressor that is frequently inactivated either by allelic loss or mutation in both familial and sporadic malignant pleural mesothelioma (MPM). Reports of BAP1 alteration in MPM are varied, and it is currently unclear if BAP1 inactivation occurs more commonly in any particular histologic subtype or if such loss of BAP1 carries prognostic significance. The potential for BAP1 analysis as a diagnostic tool also remains unknown. Design: We constructed a tissue microarray (TMA) consisting of 115 MPM cases (57 epithelioid, 48 biphasic and 10 sarcomatoid; 112 surgical and 3 autopsy). H&E and immunohistochemical staining for BAP1 were performed on the TMA and 26 reactive mesothelial controls. BAP1 nuclear staining was scored as positive or negative. Fibroblasts and lymphocytes served as internal positive controls. Survival data was obtained by chart review and statistical analysis was performed using MedCalc; autopsy cases were excluded from survival analysis. Results: BAP1 positive staining was identified in all 26 reactive mesothelial controls (100%). In contrast, staining for BAP1 was negative in 47 of 57 epithelioid (82%), 24 of 48 biphasic (50%) and 0 of 10 sarcomatoid (0%) MPM cases. Kaplan-Meier analysis demonstrated an increase in overall survival (OR 2.0433) in patients with loss of BAP1 staining (c2=9.6635, p=0.0019, 95% CI=1.1874-3.5161). However, when histological subtype was included in a Cox proportional-hazards regression analysis, BAP1 loss was no longer significant prognostically (histology: c2=13.805, p=0.0002, 95% CI=1.4569-3.0886). When only epithelioid cases were analyzed, there was a trend toward improved prognosis with loss of Bap1 that was not significant (c2=3.4619, p=0.0628, 95% CI=0.7222-6.2562). Conclusions: BAP1 staining is reliably positive in reactive mesothelial proliferations but is frequently lost in MPM, particularly in epithelioid cases. Therefore, loss of BAP1 staining likely has utility in distinguishing malignant from benign epithelioid mesothelial cells. However, while loss of BAP1 staining is associated with a relatively favorable prognosis compared to cases with retained staining, the association does not appear to be independent of histologic subtype.
Morphologic Characteristics Predictive of Outcome in Patients With Sarcomatoid Carcinoma of the Lung: A Clinicopathologic Study of 40 Cases
Mitra Mehrad, Danielle Carpenter. Washington University, St. Louis, MO. Background: Pulmonary sarcomatoid carcinomas (SC) are a rare group of non-small cell lung carcinomas, representing a spectrum of epithelial and mesenchymal differentiation. Studies have shown that these tumors are associated with a poor prognosis independent of stage at presentation. Our goal was to evaluate the clinicopathologic features and prognostic factors of this tumor. Design: We retrospectively retrieved consecutive patients with surgically treated SC from 1999 to 2012. Two study pathologists reviewed cases to confirm the diagnoses and to evaluate morphologic findings. Various histologic subtypes of the tumor were quantified. Clinical and survival data were obtained by chart review. Results: A total of 40 cases were reviewed. The mean age at presentation was 71.6 years with a median of 73.5. The majority (60%) of the patients were male. The overall survival rates at 1, 2, 3 and 5 years were 56.4%, 38.4%, 30.7% and 12.8%, respectively. Based on morphologic features, the different tumor components in order of frequency included spindle cell, glandular, squamous, giant cell, large cell, rhabdoid and true sarcoma. At univariate analyses, tumor size greater than 3 cm (p value: 0.01), stage IV disease (p value 0.004) and any amount of rhabdoid component (p value: 0.003) were strongly associated with poor patient outcome. Necrosis, vascular or pleural invasion, and histologic subtypes other than rhabdoid features did not correlate with survival. Conclusions: Although tumor necrosis and lymphvascular and pleural space invasion are important pathologic findings, they may not as significantly predict survival as stage at diagnosis and tumor size in SC of the lung, an already aggressive tumor. However, our data suggests that rhabdoid features in SC is predictive of an even more aggressive outcome in these patients and therefore need to be recognized.
Pulmonary Vascular Abnormalities in Neurofibromatosis Type 1 Patients: An Autopsy Study of 8 Cases
Wadad Mneimneh, Eunhee Yi, Jay Ryu, Anja Roden. Mayo Clinic, Rochester, MN. Background: Pulmonary abnormalities in neurofibromatosis type 1 (NF1) patients reported in the literature are relatively sparse and mainly based on clinical and radiographic findings. Although vascular changes have been reported in association with NF1, pulmonary vascular abnormalities in this setting are not well documented. Moreover, pulmonary fibrosis associated with NF1 has been debated. We systematically reviewed the histologic features in the lung tissue obtained from the NF-1 patients who underwent autopsy at our institution. Design: Autopsy files of Mayo Clinic Rochester (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) were searched for NF-1. One case was excluded due to concurrent hemoglobin S-beta thalassemia causing extensive thromboembolic vascular disease involving the lung as well as other sites. Hematoxylin-&-eosin and Movat pentachrome stained sections of both lungs were re-reviewed in all cases. Histopathologic features of interstitial, vascular, airway and pleural changes were recorded. Results: Eight patients (3 men) with NF-1 died at a median age of 53.5 years (range, 33-79) from sepsis (n=3), air embolism, pulmonary hypertension (PHT), dilated cardiomyopathy, massive internal hemorrhage due to post-operative dilutional coagulopathy, and malignant peripheral nerve sheath tumor (n=1, each), respectively. Two of these patients had a clinically documented PHT. Histologic findings are summarized in table 1.
Histologic Findings
Number of Patients (n=8) Background: Concerning clinical assessment of lung cancer, it is necessary to build a proper screening system for target oncogene mutations, especially for rare events, such as ALK, ROS1 and RET. This study is conducted to evaluate a diagnostic value of immunohistochemistry (IHC) for a screening of ROS1-altered lung cancer (ROS1-LC) and compared to fluorescence in situ hybridization (FISH). Design: Formalin-fixed paraffin-embedded specimens of surgically resected 354 primary lung cancers; 256 adenocarcinoma (Ad, including 15 genetically confirmed ROS1-positive cases) and 98 squamous cell carcinoma (Sq), were examined by IHC using anti-ROS1 antibody (D4D6). IHC results were scored in 0,1,2, based on the combination of cytoplasmic intensity and proportion. Score 0; negative, score 1; weak intensity in any percentqge or strong intensity in less than 10% of tumor cells, score 2; strong intensity in more than 10% of tumor cells.
Twenty-four IHC-positive cases (score 1 and 2) and three IHC-negative cases (score 0) were simultaneously evaluated by FISH using dual-color berak-apart style ROS1 probes. Ratio of split-positive cells were calculated by counting in 50 nuclei per case. The gene rearrangement was defined as positive when the ratio was over 30%. Results: Score 2 of ROS1-IHC was observed in 38/0 (14.8/0%) of Ad/Sq, respectively, which included all previously confirmed ROS1-positive cases. Score 1 was observed in 102/7 (39.8/7.1%) of Ad/Sq, respectively. The score 2 positivity was not only restricted to the cancer cells, but also observed in the non-neoplastic cells. Out of 27 cases examined by FISH, three cases (11.1%) were positive, which were exclusively score 2 by IHC. The majority of IHC score 2 cases did not carry ROS1 rearrangement. Sensitivity, specificity, positive predictive value and negative predictive value of IHC in this study condition were calculated as 100/100/100/13.0%, respectively. Conclusions: Our data suggested that ROS1-IHC could be used for a screening of ROS1-positive lung cancer. However, it should be mentioned that ROS1-rearrangementnegative lung cancer could exhibit overexpression of ROS1 protein by IHC. Further confirmation by another methods, such as FISH or sequencing, should be mandatory due to relatively high nonspecific positivity rate for a diagnostic application.
Metastases To the Lung From Non-Pulmonary Carcinomas After Recurrence-Free Intervals of Greater Than 5 Years
Sanjay Mukhopadhyay, Andres A Roma. Cleveland Clinic, Cleveland, OH. Background: A 5-year recurrence-free interval after resection for carcinoma is generally considered curative. Hence, a metastasis is thought to be unlikely if a lung mass develops after 5 recurrence-free years following resection of a non-pulmonary carcinoma. The aim of this study was to determine whether non-pulmonary carcinomas can metastasize to the lung after a 5-year recurrence-free interval, and if so, to determine the incidence and characteristics of such tumors. Design: Our archives (2008) (2009) (2010) (2011) (2012) (2013) (2014) were searched for metastatic carcinomas to the lung from non-pulmonary sites. The interval between resection and lung metastasis was determined by reviewing clinical and pathologic records. Cases were included in the study if: (1) the site of origin could be confidently determined on histologic grounds by immunohistochemistry and/or comparison of the lung metastasis with the primary tumor, (2) the recurrence-free interval between resection of the extra-pulmonary primary and subsequent lung metastasis was >5 years, and (3) there was no evidence of distant metastases at the time of initial diagnosis. Radiology reports were reviewed to determine the number of lung nodules at the time of lung metastasis.
Results:
We identified 187 cases of metastatic carcinoma to the lung from nonpulmonary sites. Of these, 17 (17/187, 9%) metastasized to the lung after a recurrencefree interval of ≥5 years following definitive resection of the primary cancer. These included 4 renal cell carcinomas [interval between resection and lung metastasis in parentheses] (8-33y), 4 endometrial carcinomas (8-10y), 2 colon carcinomas (9y,13y), 2 breast carcinomas (8y,12y) and one carcinoma each of the thyroid (10y), epiglottis (12y), esophagus (8y), ovary (15y) and prostate (12y). The recurrence-free interval was greater than 10 years in 7 cases (7/187, 4%). Most (12) patients had no interval chest imaging, 4 had negative interval surveillance chest X-rays and 1 had a negative chest CT. At the time of metastasis, lung nodules were multiple in 10 and solitary in 7 (2 endometrium, 1 kidney, 1 esophagus, 1 colon, 1 epiglottis, 1 breast).
Conclusions:
The possibility of metastatic carcinoma must be considered in patients with lung nodule(s) and a history of carcinoma of a non-pulmonary site, even after a recurrence-free interval of greater than 5 years. Although late metastases to the lung are uncommon, they may occur as long as 33 years after definitive resection of the non-pulmonary primary, and can present as a solitary lung mass. The most common culprits are carcinomas of the kidney and endometrium. The rarity of the mutation may limit its potential as a therapeutic option. Studies on large series of lung adenocarcinomas are under way to determine the frequency of CD74-NRG1 gene fusions in our patient population.
PHGDH and TRIM29 as Novel Diagnostic Markers for Malignant
Determination of PTEN and c-MET Status for Lung Adenocarcinoma Is Variable in Biopsy and Concurrent Excisional Specimens
Dimple Pandya, Achim Jungbluth, Natasha Rekhtman, Andre Moreira. Memorial Sloan Kettering Cancer Center, New York, NY. Background: Targeted therapy in lung cancer is an expanding field. Molecular alterations in phosphatase and tensin homolog (PTEN) and c-MET (mesenchymal epithelial transition protooncogene) are potential therapeutic targets. Loss of PTEN expression has been associated with activation of PIK3CA/AKT/mTOR pathway and is associated with sensitivity to mTOR inhibitors. Amplification or overexpression of c-MET is associated with resistance to tyrosine kinase inhibitors and/or poor prognosis. Both PTEN and c-MET can be detected by immunohistochemistry. In this study we evaluated the concordance rate of both antibodies in biopsy material and subsequent excision of the same tumor. Design: Pathology database was queried for concurrent biopsy and surgical specimens from 12/2013-7/2014. Concurrent biopsy and surgical specimens from 21 patients were reviewed to evaluate tumor histology and specimen cellularity. Immunohistochemistry with PTEN antibody clone (138G6) and c-MET antibody (clone sp44) were performed according to manufactures' instruction following a rigorous validation using positive and negative controls. PTEN staining was evaluated for complete loss of expression or retention (any cytoplasmic or nuclear stain). c-MET staining was evaluated for the intensity and extent of the staining. Positivity is defined as a strong membranous staining (2-3+) in more than 50% of the tumor cells.
Results: There was a 90% (19/21) concordance for PTEN expression between biopsy and resection (k=0.76). 6 cases showed loss of expression in the biopsy, among these cases 2 were classified as retained PTEN in the excision. In both cases the excision specimen had partial loss of PTEN. Partial loss of PTEN was seen in 3 other cases with retained PTEN in biopsy. There is a 95.2% (20/21) concordance in c-MET staining (k=0.89). In the discrepant case, the biopsy was deemed positive (2+ > 50% of tumor cells), with a negative excision (1+ >70% of tumor cells). Conclusions: Despite a good correlation between biopsy and resection for both markers, our results show there is a greater possibility of discrepant results for PTEN than c-MET because of geographic heterogenetic of expression and scoring criteria. Therefore evaluation of PTEN and c-MET staining in biopsy material should be interpreted with caution, especially when designing clinical trials for potential therapy. , lymph-vascular invasion, mitotic rate, and nuclear pleomorphism (based on nucleolar size) were recorded independent of knowledge of follow-up data. Overall survival and disease-specific survival (mean 66 months) were retrospectively determined by chart review, and development of lymph node or distant metastases. A grading system incorporating % poor prognostic growth, mitotic activity, and nuclear pleomorphism was designed on a three-point scale.
Results: By univariate analysis, nuclear pleomorphism (p<.0001), % poor prognostic growth (p<.0001), and mitotic rate (p=.007) correlated positively with lymph-vascular invasion. Nuclear pleomorphism was associated with distant metastasis (p=.006) and nodal disease (p= .0004) as was % poor prognostic growth (p=.02). Survival data by univariate analysis showed an inverse correlation between tumor grade and nuclear pleomorphism and disease specific survival (p<.001), with a lesser effect of % poor prognostic growth (p=.04). By multivariate analysis, nuclear grade was associated with overall survival independent of age, gender, and tumor size (p=.02).
Conclusions:
Grading systems for lung adenocarcinomas should include cytologic features, especially nuclear pleomorphism, as well as growth patterns.
Prognostic Significance of "Spread Through Alveolar Spaces" in Mucinous Adenocarcinomas of the Lung
Adina Paulk, Sandy Liu, Borislav Alexiev, Allen Burke. University of Maryland Medical Center, Baltimore, MD.
Background:
The recently revised WHO classification of pulmonary adenocarcinomas replaces "mucinous bronchioloalveolar carcinoma" with "mucinous adenocarcinoma," and adds tumor spread through alveolar spaces (STAS), also known as "small cluster invasion", as a type of invasion. Although micropapillary patterns of non-mucinous pulmonary adenocarcinomas can overlap histologically with STAS, the former has been associated with negative prognostic factors while the clinical significance of STAS, particularly in the mucinous subset, has not been extensively studied. Design: We retrospectively reclassified mucinous adenocarcinomas resected over a tenyear period by the WHO criteria, and correlated histologic findings, type and extent of invasion, mucin staining, and TTF-1 expression with recurrence and metastatic disease.
Results: There were 30 resections (9% of all adenocarcinomas), with a 1.3:1 female predominance. Mean age was greater in men (71 years) than in women (63 years, p=0.02). There were 2 colloid carcinomas and 28 invasive mucinous adenocarcinomas (IMA), of which 7 were entirely lepidic or minimally (< 5 mm) invasive, but classified as invasive based on size > 3 cm (n=2) or the presence of STAS (n=3). STAS was present as a combination of single cells, solid clusters, or tubules in 15 tumors, and as micropapillary structures in 7. 8 IMAs had little or no in situ component, 7 of which showed cystic (> 2mm) acinar invasive pattern. Other invasive patterns were solid / cribriform (n=11, 3 with signet ring cells), and acinar (n=13). The predominant mucin cell type was columnar with clear cytoplasm (n=14) and columnar with eosinophilic cytoplasm and intermixed goblet cells (n=16). TTF-1 was positive 13 tumors (43%), often weakly, was more frequently positive in cuboidal than in columnar cells (p<.001) and was inversely correlated with percent of mucin positive cells (p<.001). There was no correlation between mucin cell type or TTF-1 expression and type of invasion or frequency of metastasis. STAS of all types was weakly associated with distant metastasis (p=0.07) and recurrence (p=0.08), whereas micropapillary STAS was significantly associated with distant metastasis (p=.04) and recurrence (p=.03). Design: Thirty LCC were dissected by unsupervised targeted NGS analysis according to IonTorrent AmpliSeq™ Hotspot Cancer Panel v2, which identifies selected regions of 50 frequently cancer-associated oncogenes and tumor suppressor genes. Cell differentiation lineages of LCC were investigated by means of thyroid transcription factor-1 (TTF1) immunohistochemistry (IHC) for adenocarcinoma (ADC) and DNp63/p40 for squamous cell carcinoma (SQC), dichotomizing TTF1 as negative or positive (whatever extent) and p40 as negative, positive or focal if there were ≤5% reactive tumor cells. Results: While 3 LCC were wild type (all TTF1+/p40-), the remaining 27 LCC showed at least one gene mutation, whose distribution closely mirrored IHC profiles.
In particular, 7 cases with TTF1+/p40-or p40± phenotype corresponding to ADC exhibited ATM, ERBB4, FLT3, KRAS, BRAF, NRAS, TP53 or FBXW7 mutations, and 3 cases with TTF1-/p40+ phenotype pointing to SQC showed TP53 mutations only, whereas 17 cases with null (TTF1-/p40-) or unclear (TTF1-/p40±) phenotype presented ATM, BRAF, CDKN2A, EGFR, FBXW7, KRAS, PIK3CA, PTPN11, RET, SMAD4, SMO, STK11 or TP53 mutations. Frequency of mutated allelic DNA ranged from 6% (RET) to 76% (ATM). Single, double, triple, quadruple and quintuple mutations occurred in 16, 6, 2, 2 and 1 patient, respectively, with BRAF, ERBB4 and CDKN2A being mutually exclusive mutations. Tumor patients expressing ³3 mutations experienced shorter OS (p=0.001) and DFS (p=0.007), independent of tumor stage. In turn, IHC categorization did not affect survival. Conclusions: NGS analysis identified a plethora of gene mutations in LCC with close genotypic-phenotypic correlations, where TTF1/p40 null and unclear phenotypes basically corresponded to undifferentiated ADC thereby confirming on molecular grounds the IHC axiom "no p40, no squamous". Little is known about the molecular pathogenesis of neuroendocrine neoplasms primary to the thymus, which account for 2-5% of all tumors arising in this organ. Design: Nine T-NENs accounting for different histologic variants according to the current WHO classification, including 5 atypical carcinoid (AC), 3 large cell neuroendocrine carcinoma (LCNEC) and one small cell carcinoma (SCC), were investigated by immunohistochemistry (IHC) for Ki-67 labeling index and betacatenin, the latter acting as a pivotal player of the cell adhesion system at adherens junctions and main transducer of the Wnt signaling pathway to the nucleus where it activates transcription of several reporter genes. Two of these tumors also underwent unsupervised targeted next generation sequencing (T-NGS) analysis for 50 cancerassociated oncogenes and tumor suppressor genes (IonTorrent AmpliSeq™ Hotspot Cancer Panel v2).
Results: There were 8 males and 1 female, ranging from 20 to 73 years. Three out of 9 T-NENs (all LCNEC) showed cytoplasmic to nuclear decoration for beta-catenin and an intra-tumor heterogeneity of Ki-67 labeling index consistent with either spatially separated or admixed morphologic components of well-differentiated tumor (Ki-67: 10-15%) and poor-differentiated carcinoma (Ki-67: 45-75%). At variance, the remaining 6 tumors (5 AC and one SCC) presented predominantly with membrane labeling and a more homogeneous distribution of Ki-67 labeling index inside tumor mass (ranging from 10 to 90% according to histology). Exon 3 CTNNB1 gene mutations were found in the 2 LCNEC thus far analyzed by T-NGS with cytoplasmic/nuclear beta-catenin accumulation, one of which was developed as a metachronous LCNEC 17 years after a previous thymic AC harboring the same gene mutation. Conclusions: Activation of the Wnt signaling pathway by CTNNB1 gene mutation may contribute to the development of a subset of T-NENs featuring simultaneous well-differentiated tumor and poor-differentiated carcinoma, as either synchronous or metachronous lesion. These findings challenge the concept of secondary high-grade neuroendocrine carcinoma in the thymus.
Lung Cancer Ethnic Disparities: Co-Morbidity or Tumorigenicity?
Saraswati Pokharel, Umesh Sharma. Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo, Buffalo, NY. Background: Lung cancer is the leading cause of cancer related death in the United States. The incidence rate is highest among African American (AA) males followed by non-Hispanic-Whites (NHW). Earlier reports suggested that life expectancy in lung cancer patients varies between different ethnic groups. The underlying reasons for these survival disparities are not clearly known. We aim to investigate the healthrelated behavioral factors, tumor-types and tumor-grades to explain lung cancer survival discrepancies between non-Hispanic Whites, African Americans, and American Indians, treated in our minority-serving and NCI-designated cancer center. Design: Systematic review of the Roswell Park Cancer Institute's lung cancer registry from January 1996 to September 2009 was performed. Patient demographics, tumortypes, tumor-grades, smoking habits, patient survival status and the cause of death were analyzed. Results: Of the 2828 gender-matched patient cohort, 2600 (92%) were non-Hispanic whites (NHW), 204 (7%) were African Americans (AA), and 24 (1%) were American Indians (AI). More than 70% of patients of all three ethnic categories had non-small cell lung cancer-mostly grade II-III. The smoking history was positive in 92% of NHW, 89% of AA and 100% of the AI patients. Five-year survival rate was highest among NHW (18%) and lowest among AI (8%). Analysis for the cause of death revealed that 15% of AA died of the causes other than lung cancer as opposed to 21% of NHW and 25% of AI. More importantly, 70% of AA died of recurrent or persistent lung cancer in contrast to 60% NHW, and 66% of AI (P<0.05). Conclusions: Our comprehensive registry data show significant lung cancer survival disparities among three major ethnic groups. Despite comparable tumor-types and tumor-grades, mortality due to lung cancer itself is higher among AA and AI. Whether this is related to limited access to health care or due to the susceptibility for cancer recurrence-needs to be further studied. We tested 49 MM specimens in an institutional tumor profiling initiative, using targeted next-generation sequencing (NGS) of the entire exon sequence of 275 genes and selected intron coverage of 30 additional genes. The mutation profile was examined for the overall number and type of nucleotide substitutions and mutational frequency (MF) was determined. Copy number variation analysis (CNV) was also performed. The mutations were divided into four major tiers (T), T1 to T4, based on the clinical relevance for targeted therapy or prognosis of that particular mutation, with most clinically relevant mutations in T1 and T2, potentially therapeutically-targetable alterations in T3, and alterations of unknown significance in T4.
Results:
The specimens were collected from 38 (78%) men and 11 (22%) women with MM. The average age was 71 years and 58 years for male and female patients, respectively. In the male group, there were 20 (53%) epithelioid, 4 (11%) sarcomatoid and 14 (36%) biphasic types of MM. The female group consisted of 8 epithelioid (73%), 1 (9%) sarcomatoid and 2 (18%) biphasic MM. The overall mutational frequency was higher in the female group (4.64) compared to the male group (3.5). Analysis of mutational frequency by type of MM showed that the highest number of mutations are recorded in the sarcomatoid type (4.6), followed by biphasic (3.88) and epithelioid (3.54) types of MM. Among genetic mesothelioma factors the following combinations are observed: Bap1 only -6 cases (12%); 22q loss only -1 case (2%); 9p loss only -6 cases (12%); 22q and 9p loss -2 cases (4%); Bap1 and 9p loss -8 cases (16%); Bap1, 9p and 22q loss -3 cases (6%). CNV analysis showed that 19 of the 38 male patients (50%) and 6 of the 11 female patients (55%) have CDKN2A or CDKN2B deletions, this alteration being the most frequent change in chromosomal copy number observed in this study group. Conclusions: Mutational frequency differences are observed between epithelioid, sarcomatoid and biphasic types of MM that may impact on tumor behaviour. The most frequent alteration in chromosomal copy number in MM involves the CDKN2A and CDKN2B regions. A study is in progress to determine if NGS can be used to identify specific mutational patterns for asbestos-related or asbestos-independent etiology of MM.
Squamous Cell Carcinoma Mutation Profile as a Tool To Distinguish Metastatic From Primary Lung Cancer
Emilian Racila, Frank Kuo, Lynette Sholl. Brigham & Women's Hospital, Boston, MA. Background: Squamous cell carcinoma (SCC) of lung is difficult or impossible to distinguish from metastatic SCC from other sites based on morphology or immunophenotype. We hypothesized that mutational profiles as derived from nextgeneration sequencing (NGS) can be used to help distinguish these events. Design: We tested 80 SCC specimens (among 1000 total tumors) in an institutional tumor profiling initiative, using targeted NGS of entire exon sequence of 275 genes and selected intron coverage of 30 additional genes. This cohort includes 7 skin cases, 4 gynecologic (GYN) cases, 45 head and neck (H&N) cases, 1 esophageal, 3 mediastinal and 20 lung cases. The mutation profile was examined for the overall number and type of nucleotide substitutions. Mutational signatures (MUTSIG) were evaluated in all tumors with 10 or more mutations. MUTSIG were defined by the substitution type and sequence context immediately 3' and 5' to the mutated base.
Results:
The highest mutational frequency (MF), 32.6, was seen in SCC cases from skin with MUTSIG being consistent with UV-related changes in the majority of the cases, followed by significantly lower MF in GYN, H&N and lung tumors with an average number of 4.8, 7.6 and 10.3 mutations, respectively.
Among thoracic SCC cases, MUTSIG were evaluated in 11 (9 lung, 2 mediastinal) tumors. Four primary lung tumors had a C>A/G>T transversion signature characteristic of smoking-related mutagenesis. Two lung cases, had numerous dipyrimidine substitutions consistent with UV-related mutagenesis; on review of the clinical history, both patients had prior histories of cutaneous SCC. In the remaining 3 lung cases the MUTSIG was equivocal. On the other hand, both anterior mediastinal tumors, initially classified as thymic SCC, showed smoking-related MUTSIG. Conclusions: NGS can be used to distinguish lung SCC from metastatic SCC arising from cutaneous primaries using a NGS approach and an algorithm to identify mutational patterns. In this small cohort of presumed thoracic SCC, characteristic MUTSIG triggered the clinical and pathologic reclassification of 17% of tumors, including two cases of presumed lung origin reclassified as metastases from the skin and two cases of possible thymic origin reclassified as probable lung origin. Background: Chronic diffuse fibrotic lung diseases can often show areas of epithelial proliferations including honeycomb changes, peribronchiolar and squamous metaplasia with and without atypia. These changes have been postulated as an underlying mechanism for the development of lung cancer in patients with connective tissue related interstitial lung disease such as Systemic Sclerosis (SSc). Design: A single center review of all cases of lung cancer in patients with SSc was performed. Clinical, radiological, histopathological and molecular characteristics of these patients were studied. Results: 18 cases of lung cancer in SSc were identified. Majority of these patients were females (83%). 12 patients were former or current smokers with 10 to 80 pack year's history. Thirteen cases had radiographic evidence of SSc lung involvement, with nonspecific interstitial pneumonia (NSIP) being the most common pattern. The tumors comprised of 15 adenocarcinoma, 1 adenosquamous carcinoma, 1 small cell carcinoma and 1 large cell neuroendocrine carcinoma. Adenocarcinoma with either lepidic or acinar predominant pattern was the most common type of lung cancer in these patients (9/15). 7 of the adenocarcinomas had mucinous features. Five cases of resected adenocarcinoma showed multiple foci of atypical adenomatous hyperplasia (AAH) closely associated with areas of microscopic honeycombing, and transitioning into areas of lepidic and acinar predominat adenocarinoma. 9 of these tumors stained positive with TTF-1 immunostaining. Of the ten tumors which underwent molecular mutational profiling, 2 had KRAS mutation and 1 had EGFR mutation. Usual interstitial pneumonia (UIP) and desquamative interstitial pneumonia (DIP) like areas were the common pathologic patterns seen in the background lung parenchyma. Conclusions: Adenocarcinoma is the most common type of lung cancer seen in patients with SSc. The high proportion of lepidic and acinar adenocarcinomas with multiple foci of AAH, seen in our study suggests that the atypical epithelial proliferations in fibrotic lungs are the underlying pathogenetic mechanism of lung cancer development in these patients. Although these tumors are well differentiated, the tumor foci can be multiple, and hence these patients can present at higher stage disease with poor prognosis. . All cases were re-reviewed and classified according to the predominant histologic pattern (cribriform, solid, tubular). Fluorescence in situ hybridization (FISH) was employed using a break-apart strategy to detect MYB rearrangement (at 6q23.3). A Mayo laboratory-developed probe set was comprised of 5'MYB DNA labeled with SpectrumOrange dUTP (Abbott Molecular/Vysis Products) and 3'MYB DNA labeled with SpectrumGreen dUTP (Abbott Molecular/Vysis Products). 100 interphase tumor cell nuclei were evaluated per case. Medical records were studied.
Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma
Results:
The histologic patterns and clinical findings of 40 PACC are summarized in Tissue blocks for FISH studies were available in 35 cases. Disruption of the MYB gene region was observed in 12 cases whereas 17 showed no evidence of rearrangement. Six cases failed to hybridize. Follow up was available in all patients.
Conclusions: 41% of PACC harbor a MYB rearrangement. FISH studies for MYB may be of diagnostic utility in PACC, particularly on small biopsy specimens. MYB rearrangement in PACC did not appear to be associated with clinical features or prognosis.
Beyond Mitosis and Necrosis: Additional Histo-Cytologic Differences Between Typical and Atypical Carcinoids of the Lung and Their Prognostic Significance
Lauren Rosen, Ihab Lamzabi, Vijaya Reddy, Paolo Gattuso. Rush University Medical Center, Chicago, IL. Background: Well differentiated pulmonary neuroendocrine tumors (NETs) consist of typical (TC) and atypical carcinoid (AC). They are subdivided by The World Health Organization (WHO) based on mitoses and necrosis into grade 1 (TC) and grade 2 (AC). However, 10 to 20% of patients with TC die of disease within 5 years and literature regarding the histologic characteristics of these "high-risk" well-differentiated NETs is limited. To improve our recognition of higher risk subgroups of TC and AC, we investigated a cohort of cases using objective and thorough histologic criteria. Design: We searched our electronic surgical pathology records to identify cases of TC and AC. Only resection specimens, tumors larger than 0.5 cm and cases with available H&E slides were included. The H&E slides were blindly reviewed separately by 2 pathologists for an exhaustive list of histologic features. Marta Salido, Sergi Clave, Javier Gimeno, Lara Pijuan, Joana Vidal, Marta Lorenzo, Silvia Menendez, Alvaro Taus, Ana Munoz-Marmol, Enric Carcereny, Noemi Reguart, Jose Luis Mate, Joan Albanell, Sergi Serrano, Edurne Arriola, Blanca Espinet 
Characterization of ROS1-Rearrangements in a Cohort of Spanish Patients Diagnosed of NSCLC
ALK.
We observed an association with non-smoking habit (p=0.036). Regarding CNAs in ROS1 non-rearranged cases, 49.7% presented gains (3-6 copies), 30.2% deletions and 2.1% amplifications (›6 copies in >10% of tumor cells).
Conclusions:
We confirm the low prevalence described of ROS1-rearranged NSCLC cases in the Spanish population. Moreover, our study reveals a significant frequency of ROS1 deletions as a potentially relevant cytogenetic aberration, also detected in ROS1-rearranged cases. 
EGFR and ALK
Conclusions:
The combined approach of BAP1 IHC and CDKN2A FISH, although not sensitive, is very specific for diagnosing malignant mesotheliomas. The test characteristics of previously proposed markers EMA, p53, GLUT-1, IMP-3, suggest that, even in combination, these markers are not practical tools in this clinical setting.
Expression of PAK1 and PAK2 Is Associated With Grade of Pulmonary Neuroendocrine Tumors
Stephen Smith, Adam Bissonnette, David Cohen, Cynthia Timmers, Jin Jen, Junya Fukuoka, Teri Franks, William Travis, David Carbone, Konstantin Shilo Higher expression of SPT24 in lung SqCC has also been shown to be heavily influenced by the sensitivity of different detections systems. These findings with clone SPT24 led us to investigate different dilution factors, cut-off values and screening antibodies that are highly specific for lung SqCC. In this study, we will screen all lung SqCC with a multiplex cocktail of Desmoglein 3 (DSG3)/p40 and Napsin A that has been shown to be highly specific and sensitive in the detection of lung SqCC versus LADC. The SPT24 titer will be optimized for LADC and cut-off values will be examined to improve overall staining specificity without compromising staining sensitivity. Design: Formalin-fixed paraffin-embedded TMA lung SqCC (n = 137) and LADC (n = 60) were acquired. DSG3/p40 and Napsin A multiplex cocktail, TTF-1 [SPT24] and TTF-1 [8G7G3/1] antibodies were optimized for immunohistochemistry. SPT24 was optimally tittered so that normal liver was negative, unlike 8G7G3/1, which is highly expressed in normal liver. Scoring Method TTF-1 cases were considered positive if 10% or more of tumor cells were stained with a staining intensity of > 1+. Cases with <10% staining and no focal areas of positive staining were scored as negative.
Results: TTF-1 [SPT24] stained 3.6% (5/137) of lung SqCC, however, all 5 cases of lung SqCC were also positive for DSG3 + p40 (Table 1) . Napsin A was negative in all lung SqCC. In LADC, TTF1-1 [SPT24] stained 88% of cases compared to Napsin A (73.3%) and TTF-1 [8G7G3/1] (63.3%). Thus, SPT24 demonstrated high staining sensitivity (Table 2) . Conclusions: TTF-1 [SPT24] specificity is improved with titer optimization and cut-off values. Antibodies DSG3 + p40 are highly specific for lung SqCC and, therefore, may be used as a pre-screener to rule out LADC. Farnoosh Tayyari, David Hwang, Suzanne Kamel-Reid, Ming-Sound 2 ), and nuclear atypia on H&E-stained slides, performed immunohistochemistry for BAP1, and recorded p16 and NF1 status by fluorescence in situ hybridization. Overall survival was compared to a cohort of 1,342 patients aged >35 treated for PDMM during the same time period. Results: 19 (52%) men and 17 (48%) women with a mean age of 30 years (range 18 to 35) were identified. Pathologic stage was IB in 2 (6%) patients, II in 4 (11%), III in 25 (69%), and IV in 5 (14%). PDMM were epithelioid in 28 (78%), biphasic in 7 (20%), and sarcomatoid in one (3%) case. Predominant growth patterns were solid in 20 (55%) cases, tubulopapillary in 15 (42%) cases, and micropapillary in one (3%) case. The average mitotic index was 3.8 (range 1-13). Nuclear atypia was mild in 17 (47%), moderate in 12 (33%), and severe in 7 (20%) cases. BAP1 protein expression was lost in 8 (22%) cases. p16 was deleted in 4 (18%) and NF1 deleted in 15 (68%) of 22 tested cases. Personal or family history of other malignancies was present in 12 (33%) and 15 (42%) patients, respectively. 8 (22%) patients had a history of radiation for Hodgkin lymphoma. Young patients had a significantly longer overall survival than older patients (5-year overall survival rates 30.9% v 11.5%, p=0.012). Conclusions: Young patients with PDMM have a higher rate of long term survival and lower rate of p16 deletion compared to older patients. Our data confirm local radiation as a common etiologic factor, equal sex distribution, and relatively indolent course as characteristics distinguishing PDMM in young patients. Stage distribution, histology, and BAP1 loss are similar in young and older patients. Our results indicate that certain clinicopathologic characteristics of young patients with PDMM are distinctive, suggesting unique biological behavior despite some similarities to PDMM in older patients, reflecting the biologic complexities of this disease. Background: Phophatase and tensin homolog (PTEN) is a tumor suppressor gene and negative regulator of PI3K/AKT/mTOR pathways. PTEN loss of function is associated with response to inhibitors of these pathways. Deleterious gene-level PTEN alterations have been reported in up to 11% of squamous cell carcinomas (SqCC) and 2-3% of adenocarcinomas (ACA) in the lung. While immunohistochemical (IHC) detection of PTEN protein loss has been shown to correlate with gene alterations in endometrial and prostatic adenocarcinomas, it has not been well-characterized in non-small cell lung carcinoma (NSCLC). The aim of this study is to correlate PTEN IHC with gene-level changes in NSCLC. Design: PTEN mutation and copy number were determined by targeted exon hybrid capture library preparation (Agilent) and next generation sequencing (NGS) using the Illumina HiSeq 2500. Mutation calls were generated using MuTect and GATK, copy number calls using VisCap Cancer, and large structural variants using BreakMer. PTEN IHC (Cell Signaling; clone 138G6) was performed on 4 micron formalin-fixed paraffin embedded tissue sections following pressure cooker antigen retrieval. Extent of staining was graded in 10% increments and intensity on a scale of 0-3 (from absent to strong relative to internal control) and multiplied to calculate an H-score. IHC was also graded by two pathologists to assess interobserver reproducibility.
Gene Mutation Frequencies and Associations in Adenocarcinoma of the Lung
Results: 152 tumors were tested, including 122 (80%) ACA, 22 (14%) SqCC, 7 (5%) unclassified NSCLC, and 1 (1%) atypical carcinoid. Overall, 11 (7%) patients had PTEN gene mutation or homozygous deletion, including 8 (6.5%) ACA and 3 (14%) SqCC. PTEN IHC expression was absent in 15 cases, 1-100 in 92, 101-200 in 41 and 201-300 in 4. Of tumors with gene-level PTEN alterations, 8 (73%) had absent PTEN expression and 3 (27%) had an H-score of 1-100. 7 (5%) patients without PTEN aberrations had absent expression. Interobserver agreement was good (Kappa coefficient 0.657). Absence of PTEN expression by IHC is 73% sensitive and 95% specific for a deleterious genetic event. Conclusions: Complete loss of PTEN expression is highly specific for a deleterious gene-level alteration in PTEN. Alternative mechanisms of silencing such as DNA methylation may account for loss of expression in the absence of genetic alterations. Low level PTEN expression is frequent in NSCLC and does not specifically predict gene-level alterations.
Can Next Generation Sequencing Help Distinguish Multiple Primary Pulmonary Adenocarcinomas From Intrapulmonary Metastases?
Ann Walts, Andy Pao, Alberto Marchevsky, Jean Lopategui. Cedars-Sinai Medical Center, Los Angeles, CA. Background: Distinguishing independent primary pulmonary adenocarcinomas (PA) from metastases impacts management and prognosis but can be difficult in practice. Previous next generation sequencing (NGS) studies have shown that metastatic tumors generally retain at least some of the same mutations as the primary lesions. Design: Tumors from 7 patients (5 with synchronous bilateral PA resected within 6 months, one with synchronous PA and tumor in the small intestine, and 1 with metachronous contralateral PA resected 12 years apart) were selected from our pathology database for study. Only the patient with metachronous tumors received chemotherapy prior to NGS. DNA extracted from macrodissected formalin fixed paraffin embedded sections of the 15 tumors was analyzed for 2855 hotspot mutations (HSM) in 50 genes using the IonAmpliSeq™ Cancer Hotspot Panelv2 (Life Technologies Corp., Grand Island NY) per the manufacturer's recommendations. The laboratory's limit of detection (LOD) is 10% at 250X coverage. NGS results were compared per patient. Results: Synchronous PA (n=11): 10 HSM (3 KRAS, 3 TP53, 2 EGFR, 2 BRAF) were identified in 9 of the 11 tumors from 5 patients with synchronous bilateral PA (1 patient with 3 synchronous PA). The HSM per tumor ranged from 0 to 2. HSM were different in the synchronous tumors from all 5 patients. These findings support the diagnosis of independent synchronous lesions in each of these patients. Synchronous metastatic tumors (n=2): Both tumors from the patient with a PA and a synchronous intestinal tumor showed identical KRAS and APC-HSM, findings supporting the diagnosis of metastasis. Metachronous PA (n=2): NGS identified 4 HSM (1 in each gene: KRAS, TP53, KIT, and CDKN2A) in the initial PA and a different TP53-HSM in the subsequent tumor. Although the 2 tumors exhibited morphologic similarities, the NGS findings support independent primaries or loss of 4 original HSM and gain of a new TP53 HSM as a result of therapy related mutation and/or branched evolution. Conclusions: -NGS is a potentially useful tool for categorization of multiple pulmonary PA as either independent primaries or metastases.
-Bilateral PA with different and distinct mutations should probably be classified as independent primaries while tumors with identical mutations are probably metastatic.
-The findings are difficult to interpret in metachronous tumors especially after treatment. -NGS studies with additional patients and clinical outcome are needed to determine if this categorization can be used for staging and management. 
Background:
The distinction between thymoma and non-neoplastic thymic tissue (NNTT) can be difficult in selected cases, resulting in diagnostic and staging problems. The potential role of the squamous markers desmoglein-3 (DSM) and p40 in this differential diagnosis has not been investigated. Design: Selected slides of 5 normal thymus, 5 hyperplastic thymus, and 57 thymomas including WHO type A (n=2), AB (n=16), B1 (n=15), B2 (n=16), and B3 (n=8) from our pathology files were immunostained using desmoglein-3 (BC11) and p40 antibodies (both from Biocare, Concord CA). The immunostained slides of 35 of the thymomas included adjacent NNTT. Cytoplasmic/membranous or nuclear staining in ≥ 10% of the neoplastic and/or NNTT was recorded as DSM-positive or p40-positive, respectively. Staining in <10% of the thymic epithelial cells was recorded as negative. DSM and p40 expression in each thymoma was compared with expression in NNTT, including normal and hyperplastic glands and thymic tissue adjacent to the thymoma. Results: Thymic epithelial cells in all (100%) thymomas and NNTT were positive for p40 in a diffuse distribution pattern proportional to the density of thymic epithelial cells. The p40 immunostain did not help distinguish or delineate thymoma from NNTT. All (100%) NNTT expressed DSM in an "organotypic" distribution pattern with immunoreactivity observed in subcapsular, medullary, and only focal cortical epithelial cells and Hassall's corpuscles. Sheets of DSM-positive epithelial cells highlighted the presence of thymic hyperplasia. In contrast, only 35 (61.4%) of the thymomas were DSM-positive; the remaining 22 (38.6%) were DSM-negative. 18 of these 22 cases had adjacent NNTT and in each case the NNTT was DSM-positive, serving as an internal positive control for the immunostain. Conclusions: Normal and hyperplastic thymus, and 61.4% of thymomas express DSM in an "organotypic" distribution pattern. Negative immunoreactivity for DSM in 38.6% of thymomas can be helpful to distinguish these neoplasms from NNTT and to delineate tumor extension. The presence of DSM-positive and -negative thymomas suggests that these tumors may originate from 2 different types of thymic epithelial cells. As DSM is expressed predominantly in medullary and subcapsular thymic epithelial cells, the possibility that DSM-positive thymomas arise from these cells rather than from cortical cells or Hassall's corpuscles warrants investigation.
Anatomic Distritubion of Smoking-Related Interstitial Fibrosis (SRIF) in Lung Lobectomy/Pneumonectomy Specimens
Rebecca Waters, Mahmoud Eltorky, Gurinder Singh, Shawn Nishi. University of Texas Medical Branch, Galveston, TX. Background: Smoking-related interstitial fibrosis (SRIF) is a common finding in smokers with distinct pathologic features from other chronic fibrosing lung diseases. The reported morphological features include a patchy, subpleural distribution of ropy, eosinophilic collagen within alveolar septae in the upper lobes of the lungs, often in a background of emphysema and respiratory bronchiolitis. Unlike other interstitial lung diseases (ILD), SRIF has a much more favorable prognosis. Therefore, it is important to classify SRIF as a distinct diagnosis. Our objective was to investigate the frequency of SRIF with regards to anatomic distribution in lung-resected specimens and its relation to pulmonary function tests (PFTs) and radiological findings. Design: Non-neoplastic slides from patients with past lobectomies, pneumonectomies, smoking history, and primary lung cancer (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) were reviewed (n=90) for presence of SRIF. The following sets of data were recorded: Patient age, gender, smoking history, radiological findings, tumor location, pathological diagnosis, PFT results, history of collagen vascular disease, tumor stage, and follow up care. Carcinoid tumors from previous pneumonectomy specimens in patients without smoking history were reviewed and used as controls (n=5). Results: SRIF was identified in 39% (n=35) of the cases. Sixty percent (n=21) were located in the upper lobe, 11% (n=4) were in the middle lobe, and 29% (n=10) were in the lower lobe. Seventy-one percent (n=25) were male and 29% (n=10) were female. The average age was 67 years. No cases (n=0) had a recorded history of collagen vascular disease. A review of PFTs revealed 49% (n=17) with obstructive disease, 11% (n=4) with normal spirometries, 3% (n=1) with obstructive and restrictive disease, and no (n=0) cases of restrictive disease. Thirty-seven percent (n=13) of patients had no PFTs. The possibility of amyloid deposition was eliminated by negative staining with Congo-red. The number of pneumocytes lining the restricted alveolar lining of SRIF was significantly lower when compared to adjacent normal alveoli by Thyroid Transcription Factor 1 (TTF1) immunohistochemical staining. Conclusions: SRIF is a common entity in smokers affecting all lung lobes with minimal clinical presentation and must be recognized and separated from other forms of interstitial lung fibrosis. Background: Thymic epithelial neoplasms (TEN) are rare tumors which are incompletely understood and lack standardized treatment approaches. An emerging new strategy in cancer treatment is the blockade of immune checkpoints. Programmed death 1 (PD1) is a key immune checkpoint receptor expressed by activated T cells which mediates immunosuppression by binding to its ligand PD-L1 on the surface of tumor cells. Inhibition of this pathway using monoclonal antibodies against PD1 or PD-L1 is emerging as an effective treatment alternative. Overexpression of these molecules detectable by immunohistochemical methods is thought to be a potential biomarker for treatment response and durable drug effects have been demonstrated in some solid tumors and lymphomas. Here, immunohistochemical overexpression of PD1 and PD-L1 was investigated in 100 cases of TEN in order to evaluate the potential use of such treatment in these tumors. Design: One hundred cases of TEN [26 thymic carcinomas, 25 spindle cell thymomas (WHO type A), 25 conventional thymomas (WHO B1/B2) and 24 atypical thymomas (WHO B3)] were reviewed and representative whole tissue sections from thymectomy specimens were selected for immunohistochemical studies using antibodies directed against PD1 and PD-L1. The percentage of positive tumor infiltrating T-cells and tumor cells, respectively, was evaluated and scored. Cases with strong membranous reactivity of the antibody on ≥5% of T-cells (PD1) or tumor cells (PD-L1) were considered positive. Results: Overexpression of PD1 was detected in 10/26 thymic carcinomas (38%), 16/25 spindle cell thymomas (64%), 23/25 conventional thymomas (92%), and 14/24 atypical thymomas (58%). Positive PD-L1 cases included 14/26 thymic carcinomas (54%), 17/25 spindle cell thymomas (68%), 19/25 conventional thymomas (76%), and 19/24 atypical thymomas (79%). In combination, a total of 87 (87%) cases showed overexpression of PD1 and/or PD-L1 (thymic carcinoma: 16/26, 62%; spindle cell thymoma: 23/25, 92%; conventional thymoma: 25/25, 100%; atypical thymoma: 23/24, 96%). Conclusions: PD1 and its ligand PD-L1 are immunohistochemically overexpressed in 87% of TEN and may be the cause of an immunosuppressive environment in these tumors. Our results suggest that TEN may be another group of tumors that should be considered for PD1/PD-L1-targeted therapies. Clinical trials to investigate the use of these immune-checkpoint inhibitors in patients with TEN may be indicated. Background: Pulmonary spindle cell carcinoma (PSCC) is a rare tumor currently classified as a subtype of sarcomatoid carcinoma, a group of tumors with an aggressive clinical course. Their low incidence coupled with a lack in uniformity of terminology and diagnostic criteria has impaired the development of systematic treatment strategies for these tumors. We report the clinicopathological and immunohistochemical features of 40 PSCC. Design: Sixty-five cases of resected sarcomatoid carcinomas of the lung were identified from our surgical pathology files. Forty cases fulfilling the criteria of PSCC (spindle cell component ≥90%) were analyzed for clinicopathological parameters. In 30 cases, immunohistochemical studies with antibodies directed against CAM5.2, CK5/6, p40, CK7, TTF-1, napsin A, calretinin and D2-40 were performed. Results: The patients were 22 males and 18 females aged 42 to 86 years (mean 62.4). Main presenting symptoms included chest pain, shortness of breath and hemoptysis. Thirty-three patients had a smoking history. Histologically, the tumors were composed of malignant fusiform cells growing in interlacing fascicles. Twenty-seven cases were pure PSCC; 13 cases had an additional minor component (<10%) of conventional nonsmall cell carcinoma. Immunohistochemically, the spindle cells were characterized by consistent reactivity for CAM5.2 (97%) and variable expression of CK5/6 (17%), p40 (13%), CK7 (80%), TTF-1 (37%), napsin A (10%), calretinin (13%) and D2-40 (7%). Twenty-six patients received chemoradiation therapy. Clinical follow-up showed that 28 patients had died 1 to 28 months after diagnosis (mean survival 10.9) and 8 patients were alive with a follow-up period from 17-165 months (mean 89). Conclusions: PSCC primarily affect patients in the 7 th decade with equal gender distribution and a strong association with smoking status. Although some authors consider pulmonary sarcomatoid carcinomas to be an independent clinicopathological entity, a significant number of our PSCC express immunohistochemical markers associated with the more common lung tumors. This not only supports the notion that these tumors may represent poorly differentiated non-small cell carcinomas but also raises the question if PSCC should be separated from the other tumors of the sarcomatoid carcinoma group. PSCC run an aggressive clinical course with a mean survival of only 10.9 months. Rigid pathological criteria and focused clinical studies are needed to guide future therapies and improve patient outcome.
Computational Discovery of Prognostic Morphologic Features in Squamous Cell Carcinoma of the Lung
Daniel Xia, Ruben Casanova, Alex Soltermann, Andrew Beck. Beth Israel Deaconess Medical Center, Boston, MA; University Hospital of Zurich, Zurich, Switzerland. Background: Microscopic examination of tissue histomorphology is critical for the appropriate classification of human malignancies into theranostic categories. In the western hemisphere, squamous cell carcinoma of the lung is the second most common histologic subtype of non-small cell lung cancer (NSCLC), accounting for approximately 30% of all NSCLC. In comparison to lung adenocarcinomas (as outlined in Travis et al.), relatively little is known about the histologic features that predict survival in squamous cell carcinomas. The goal of our study is to use a computational approach to identify prognostic histologic features in lung squamous cell carcinomas. Design: Quantitative computational analysis was performed using the Definiens Tissue Studio software on digital tissue microarray (TMA) images. 1536 morphologic features (describing the nuclear, cytoplasmic, and global features of the cancer stroma and epithelium) were quantified for each of 468 TMA images from 234 patients with squamous cell carcinomas of the lung. Overall survival status, progression free survival status, and days to last follow-up were available for each patient. Significance of microarray (SAM) analysis was performed using R to identify features significantly associated with overall survival, after adjusting for multiple comparisons (cutoff is False Discovery Rate <0.05). For each feature significantly associated with survival, the 10 numerically highest and 10 lowest ranked images were selected for manual review by visual inspection. Results: 4 morphologic features were significantly associated with overall survival (FDR < 5%). The manual review of images showing extreme values for the 4 features suggests that these features capture the presence or absence of stromal inflammatory cells and/or necrotic debris, which is associated with poor prognosis (see figure 1) . Conclusions: Quantitative computational analysis of digital pathology images may be an efficient "hypothesis generator" for morphologic discovery in human malignancies. Future studies will aim to validate our results on additional cohorts and to study the underlying molecular basis.
Reliable Detection of ALK Gene Fusions in Lung Cancers By
Hybrid Capture-Based Next-Generation Sequencing: High Concordance With ALK FISH and ALK IHC Roman Yelensky, Amy Donahue, Zach Chalmers, Geoff Otto, Michelle Nahas, Jie He, Frank Juhn, Garrett Frampton, Juliann Chmielecki, Jeffrey Ross, Vincent Miller, Philip Stephens, Doron Lipson, Julianna Eng, Andre Moreira, Lu Wang, Ryma Benayed, Ahmet Zehir, Ronak Shah, Donavan Cheng, Michael Berger, Maureen Zakowski, Marc Ladanyi. Foundation Medicine Inc, Cambridge, MA; Albany Medical College, Albany, NY; Memorial Sloan Kettering Cancer Center, New York, NY. Background: Hybrid capture-based (HCB) next-generation sequencing (NGS) assays have the potential to detect all classes of genomic alterations (missense and indel mutations, copy number alterations, select structural rearrangements) in multiple cancer genes in a single test. Here, we report the performance characteristics of two independent HCB NGS assays in detecting one of the most clinically significant gene fusions in solid cancers, ALK gene fusion in lung adenocarcinomas (LUAD).
Design:
We evaluated fusion gene detection by FoundationONE, an HCB NGS test for all exons of 287 cancer genes, with deep sequencing of commonly rearranged introns in 19 (or, in alternative version, 31) genes. We created reference samples for sensitivity analyses by admixing 5 gene fusion-bearing cell lines (2 ALK, 1 RET, 1 ROS1, 1 TMPRSS2) into 22 different pools, such that each fusion was represented at simulated cellular fractions of 100%, 50%, 33%, 25%, and 20% at least once. Gene fusions were called if 5 or more chimeric reads were observed in a targeted intron. We tested 45 LUAD (22+/23-) FFPE clinical samples previously studied by ALK FISH (Abbott) or ALK IHC (antibody D5F3; Cell Signaling). In parallel, we optimized and validated a similar but independent assay, MSK-IMPACT, that interrogates 341 cancer genes and commonly rearranged introns in 14 cancer fusion genes. Results: Of 32 tested gene fusion instances in the 22 cell line pools, all were detected by FoundationONE, down to 20% simulated tumor content, with no false positives. Among the clinical FFPE samples, of the 22 ALK FISH+ specimens (range of FISH+ nuclei: 17-86%; 9/9 also ALK IHC+), 20 were unequivocally + by FoundationONE, with the remaining 2 specimens showing marginal evidence of the events, while 22/23 FISH-negative specimens were also negative by FoundationONE, with the remaining specimen a possible false negative by FISH. The similarly designed MSK-IMPACT assay underwent preclinical optimization which showed that reliable detection of ALK fusions was achieved with approx. 500X coverage of ALK intron 19 (lower coverage, such as 100X, resulted in a high false negative rate). In prospective clinical testing using MSK-IMPACT, 4 EML4-ALK cases have been detected, all 4 also positive by ALK IHC (4/4) or ALK FISH (2/2). Conclusions: HCB NGS assays that include baits for commonly rearranged introns can reliably detect clinically actionable gene fusions such as those involving ALK in LUAD. 
Background:
The presence of EML4-ALK fusion as a consequence of ALK gene rearrangement is a useful biomarker to predict therapeutic responsiveness to anti-ALK agent such as Crizotinib in a subset of non-small cell lung cancer. The gold standard assay for detection of ALK rearrangement is by FISH analysis. Formalin fixation time is a known preanalytic variable that may interfere with FISH testing, we studied its effect on ALK testing in various types of clinical specimens. Design: A total of 246 specimens including cytology cell block from fine needle aspiration and body cavity fluids, trans-brachial biopsy, frozen section, resection specimens for both primary and metastatic lesions were studied. Based on tissue fixation time in formalin before processing, the specimens were divided into two groups using 6 hours fixation time as an arbitrary cutoff. 169 cases had more than 6 hours formalin fixation while 77 cases had less than 6 hour fixation. FISH analysis was performed on all specimens using Vysis LSI ALK Break Apart Rearrangement probe (Abbott Molecular, Des Plaines, IL) according to the manufacturer recommended protocol. Signal patterns (patchy vs. diffuse) and repeat rates were compared between the two groups. Statistical analysis was performed using Fisher exact test. Results: As shown in table 1, the repeat rates are significant increase in less than 6 hours fixation group (P<0.001). The signals are also very patchy in this group. Groups of tumor cells most at peripheral have some signals while groups of tumor cells most in the center have no signals or scattered signals. The specimens were repeated if signals were too patchy and not reliable. After modifying the protease digestion time, most cases resolved and results obtained. However, there are 4 cases which could not be scored due to too poor signal quality. Conclusions: Accurate assessment of ALK gene rearrangement by FISH is critical for identifying patients with NSCLC who may benefit from ALK inhibitor therapy. Our data indicate that insufficient formalin fixation time (<6 hrs) is an important preanalytical variable negatively affecting ALK FISH testing. Similar to HER2 testing in breast carcinomas, a guideline on minimal fixation time for ALK testing may be necessary. Akira Yoshikawa, Tomonori Tanaka, Mikiko Hashisako, Yukio Kashima, Hiroki Karata, Kazuhiro Tabata, Junya Fukuoka . Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Background: Construction of three dimensional (3D) image using series of two dimensional pictures is a common method for radiology. Observing 3D surfaces is efficient for providing easy understanding of the structure and detecting the unnoticeable tiny changes. To unveil pathogenic temporal sequential event of emphysema, we developed a method to observe lung specimen in 3D and compared normal-looking lung from patients with and without emphysema. Design: 15 cases of lobectomy specimen each with and without emphysema were selected. One block for each case selected was cut for 300mm thick section, then
3D Pathology Construction Reveals Framework Structure of the Lung and Increase of Pores of Kohn as an Initial Event of Emphysema
